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List of abbreviations1 
 
ABP activity based probe 
Ac acetyl 
Ada 1-adamantyl acetyl 
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FRET fluorescence resonance energy 
 transfer 
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GFP green fluorescent protein 
GM-CSF granulocyte macrophage-colony 
 stimulating factor 
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HIV human immunodeficiency virus 
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Pbf 2,2,4,6,7-pentamethyldihydrobenzo-
 furan-5-sulfonyl 
PBMC peripheral blood mononuclear cell 
PBS phosphate buffered saline 
Pmc 2,2,5,7,8-pentamethylchroman-6-
 sulfonyl 
ppm parts per million 





RNA ribonucleic acid 
RP reverse phase 
RPMI Roswell Park Memorial Institute 
rt retention time 
s singlet 
sat. saturated 
SDS sodium dodecyl sulfate 





tBu tert butyl 
TES triethyl silane 
Tf trifluoromethylsulfonyl 
TFA trifluoro acetic acid 
THF tetrahydrofuran 
TIS triisopropyl silane 
TLC thin layer chromatography 
TMEDA N,N,N',N'-tetramethylene 
 ethylenediamine 
TMS tetramethyl silane 
Tr triphenylmethyl 




1. The one and three letter codes for the amino 
acids follow the recommendations of IUPAC. 
J. Biol. Chem. 1968, 243, 3557-3559 and J. 











This thesis describes the development of strategies to study the proteasome and 
cysteine proteases of the cathepsin family. Key to all strategies is the use of an electrophilic 
trap, which allows covalent labeling of the proteolytic activities with a number of desirable 
properties, depending on the question at hand. The development of such labels, often based 
on irreversible inhibitors, is not unique to this thesis. Indeed, many research efforts on the 
development of irreversible protease inhibitors have appeared in the literature over the past 
decades.1 These probes are widely regarded to be very useful in medicinal and biological 
research, both for the purpose of drug development and, perhaps more importantly, for the 
assessment of protease activities in complex biological samples in what is now called 
chemical, or functional, proteomics.2 
An ideal protease label in the field of proteomics should have a number of 
functionalities embedded in its structure. These include comparable and high binding to all 
members of a given class of proteases, but no reactivity towards other components in the 
biological sample. Other useful attributes are cell permeability and the means to track (for 
instance via a fluorescent tag) and/or retrieve the modified proteases. A further attractive 
feature would be the ability to monitor the relative abundance or proteolytic activities 
stemming from different, but closely related biological samples. Obviously, such ideal tools 
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are not within reach for each class of proteolytic activities present in nature. The first 
requirement is the ability to covalently and irreversibly modify proteolytic activities. This 
can be achieved with relative ease in case a side chain heteroatom of the protease(s) at hand 
participates in proteolysis, exerting a nucleophilic attack on the peptide bond of the 
substrate. Fortunately, this is the case for many protease families,1 for instance the 
threonine secondary alcohol (the proteasome), the serine primary alcohol (serine proteases 
such as trypsin) and the cysteine thiol (many cathepsins, caspases, ubiquitin isopeptidases). 
The highly reactive nucleophiles can be used as a site for labeling of the protease via 
selective alkylation. However, protease families that recruit a water molecule for the initial 
nucleophilic attack (matrix metalloproteases, aspartic proteases) have proven to be more 
resistant towards chemical proteomics strategies employing protease inhibitor tools.3 A 
broad spectrum irreversible protease inhibitor is an appropriate starting point for designing 
protease labels. Some restraint is required, though, because covalent attachment of an 
identification or isolation tag to a broad spectrum irreversible protease inhibitor may 
abolish cell permeability or may result in a drop in activity.4 
The aim of this thesis is to address some of the issues raised in the previous 
paragraph. In case it is not possible to include all desirable properties of broad spectrum 
activity, cell permeability and identification potential in one chemical probe, an alternative 
would be to modify proteases in a two-step procedure: first labeling with a cell-permeable 
probe and second selectively functionalizing the labeled protease with an identification 
moiety in a cell-free environment. One solution, presented in this thesis for the two-step 
labeling of the proteasome, relies on the use of the Bertozzi-Staudinger ligation,5 one of the 
major recent breakthroughs in the development of selective reactions in complex mixtures 
of biological origin. A second advance in protease probe design is the inclusion of an 
isotope encoded spacer, described in this thesis as a set of ‘light’ (H8) and ‘heavy’ (D8) 
probes that inhibit a broad array of cathepsin cysteine proteases. This strategy extends the 
isotope coded affinity tagging (ICAT) strategy as developed by Aebersold and coworkers,6 
enabling the monitoring of relative levels of protease activity, rather than levels of 
expression. The ICAT strategy is based on the alkylation of cysteine residues in two 
samples with either a heavy or light reagent, the mass difference of the products stemming 
from isotopes incorporated. The underlying idea is that the incorporated stable isotopes 
neither influence the reactivity of the alkylating agent towards cysteine thiols nor influence 
its chromatography properties. The two samples are combined and prepared for mass 
General introduction 
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spectrometric analysis, where fragments containing alkylated cysteine residues serve as 
mutual internal standard. The relative abundance of proteins in the two samples becomes 
apparent through comparing the magnitudes of the signal pairs originating from cysteine 
containing fragments. 
Although the probes described in the research chapters in this thesis can be used to 
study either the proteasome or the cathepsin family of cysteine proteases, the general 
strategy upon which their design is based should be easy to transfer to probes for studying 
other classes of biomolecules. As such, the contents of this thesis fall within the broad area 
of research that can be described loosely as ‘Chemical Biology’.7 Although not new, 
especially the last decade has witnessed an explosion of research activities that take place at 
the interface of chemistry and biology. Next to the two examples briefly outlined above 
(bioorthogonal labeling, ICAT based proteomics), diverse areas of research such as 
chemical genetics (disabling gene products through inhibition with a chemical compound, 
rather than silencing the gene),8 but also engineering the actual genetic code9 are considered 
to belong to the Chemical Biology area. A specific area of Chemical Biology research with 
high relevance for part of the contents of this thesis is highlighted in Chapter 1 and 
encompasses the current status in the two-step labeling of selected biomolecules in live 
cells. 
Chapters 2 and 3 describe a new strategy to decorate the proteolytic activities of 
the 26S proteasome with a biotin moiety in a two-step strategy. The 26S proteasome is the 
business end of the ubiquitin-proteasome machinery that is responsible for the degradation 
of the majority of cytosolic and nuclear proteins in eukaryotes.10 The degradation and 
turnover of proteins is indispensable for living cells, both to remove malfunctioning or 
redundant proteins, and to allow reuse of amino acids in the synthesis of other proteins. 
Attachment of a polyubiquitin chain (ubiquitin is a 76 residue signal protein) to lysine 
residues in a given protein marks it for degradation. The proteasome processes 
ubiquitinylated polypeptides to produce oligopeptides of a length varying from three to 
about 20 amino acid residues. The bulk of these are then further processed through the 
action of downstream aminopeptidases. A small portion, however, will (after potential 
further trimming by aminopeptidases) escape to the endoplasmic reticulum and complex to 
major histocompatibility complex (MHC) class I assemblies for presentation to the immune 
system.11 As such, the proteasome is indispensable to mammalian immunity in monitoring 
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the cytosolic and nuclear protein content which may, next to self proteins, also encompass 
viral encoded proteins. 
The 26S proteasome is assembled from a 20S core proteolytic particle to which two 
19S cap protein assemblies are associated. Substrate recognition takes place at the 19S 
caps, where also protein unfolding and ubiquitin removal activities are located. The actual 
protein degradation takes place within the 20S core particle, which consists of 28 protein 
subunits. Of these, 14 α-subunits make up the outer parts as two rings of 7 subunits each, 
and 14 β-subunits make up the inner parts, again as two rings of 7 subunits. The 7 α-
subunits in each ring, although highly homologues, have an unique sequence and the same 
holds true for the 7 individual β-subunits in the inner rings. Three of the β-subunits in 
higher organisms possess catalytic activity, each with a distinct (although as yet poorly 
understood) substrate preference. To complicate matters further, higher organisms may 
express a second set of proteasome proteolytic activities, which also assemble into a 20S 
particle. This particle, induced by specific cytokines (for instance interferon gamma) that 
are the result of initial immune response processes, is therefore called the 
immunoproteasome,12 and it also harbors three distinct catalytic activities. In Chapter 2 a 
two step labeling strategy is described that enables the visualization of the combined six 
proteolytic activities of both the constitutively expressed proteasome and the 
immunoproteasome with almost equal efficiency. The strategy hinges on the use of two 
synthetic tools, one being a peptide vinyl sulfone broad spectrum proteasome inhibitor 
equipped with an azide, and the other a biotinylated phosphine. After addition of the vinyl 
sulfone compound to growing cells, labeling of all proteasome catalytic subunits with azido 
groups occurs. Cell lysis is followed by denaturation of the protein content. In the next step 
the azide functionalities are addressed through Staudinger ligation, resulting in the 
attachment of a biotin to each catalytic subunit. These are now visualized through SDS-
PAGE gel electrophoresis followed by streptavidin blotting. Chapter 3 describes the 
application of this two-step labeling strategy in the identification of a peptide vinyl sulfone 
based inhibitor that specifically inhibits one of the three proteasome proteolytic activities, 
namely the one with preference to cleave after acidic residues (β1 or the caspase-like 
activity). Further, this inhibitor was found to specifically inhibit the corresponding 
immunoproteasome subunit (β1i), making this compound potentially useful in the study of 
the involvement of the immunoproteasome in MHC class I antigen presentation. 
General introduction 
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Chapters 4, 5 and 6 describe the development of tools to modify and analyse 
lysosomal cysteine proteases of the cathepsin class.13 Lysosomal proteases, of which the 
cathepsins constitute the major class, are responsible for the degradation of proteins that are 
collected into the lysosomal compartment through phagocytosis, pinocytosis or autophagy. 
Proteins targeted for lysosomal degradation can be either cell surface membrane associated 
proteins or proteins from the extracellular matrix, and may be either self proteins or 
proteins originating from host pathogens, typically bacteria. As such, the body of lysosomal 
proteases complement the ubiquitin-proteasome pathway, in that the latter degrades most 
intracellular proteins and the former takes care of the extracellular protein content. Another 
parallel is their role in the adaptive immune system: a small portion of the oligopeptides 
resulting from lysosomal proteolysis escape further degradation and are presented on the 
cell surface by MHC class II molecules.14 In this way, also the protein content of the 
extracellular matrix, including that arising from bacterial infection, is monitored by the 
immune system. This thesis describes the development of a number of advanced chemical 
probes for the study of cathepsin activity in a number of different settings. All probes are 
based on the leucine epoxysuccinate motif as present in the parent compound known in the 
literature as DCG-04,15 which was developed by Bogyo and coworkers as a broad-spectrum 
cysteine protease label. Chapter 4 presents the development of a set of isotope-encoded 
activity based probes for the assessment of the relative abundance of cysteine proteases. 
The probes are based on the aforementioned DCG-04, but contain either eight protons or 
eight deuterium nuclei. The first inroads towards the use of these compounds in biological 
studies and the difficulties in these are discussed. In Chapter 5 a strategy is presented 
through which the progress of an extracellular protein through the endocytic pathway and 
the cysteine proteases it encounters along that way can be monitored.16 A broad-spectrum 
cysteine protease label equipped with a biotin moiety is linked to ovalbumin as a model 
protein through a photocleavable linker. Initial studies in which the conjugate is incubated 
with recombinant cathepsin S followed by photocleavage are presented. Chapter 6 makes 
use of a related strategy. A cysteine protease probe is linked to nona-arginine, a peptide 
known for its ability to deliver cargo to the cytosol.17 Endocytosis studies demonstrate that 
this conjugate labels at least some of the pool of cathepsin cysteine proteases, thereby 
indicating that cell penetrating peptides of this type do make use of endocytic processes in 
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Bioorthogonal chemistry in living cells: 




Research in contemporary life sciences is increasingly directed towards the detailed 
analysis of biological processes at the molecular level. In order to understand and intervene 
in processes at the DNA/RNA level, protein-protein interactions and enzymatic action - 
systems which all involve large biopolymers - a detailed insight into structural and 
chemical mode of action is often a prerequisite. At the same time, scientists endeavour to 
generate such detailed molecular information from macroscopic systems, that is, in whole 
cells and organisms. 
The ability to selectively tag a biomolecule in living cells or organisms allows 
researchers to a) monitor its involvement in a given biological event which progresses in its 
natural environment, and/or to b) retrieve and analyse in detail the tagged biomolecule or its 
metabolites. The biomolecular toolbox provides a set of useful tags which can be attached 
to proteins of interest through standard genetic engineering techniques. Widely used tags 
include short oligopeptide stretches that can be selectively isolated through 
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immunoprecipitation (such as the FLAG tag) or affinity chromatography (for instance the 
nickel-binding His tag). Of particular interest is the family of fluorescent proteins, the most 
prominent member of which is green fluorescent protein (GFP).2 
The availability of fluorescent proteins emitting at different wavelengths has 
resulted in the development of fluorescence resonance energy transfer (FRET)3 strategies 
for the visualisation of the spatial arrangement and interaction dynamics of proteins. In the 
last decade, a wealth of information on many biological systems has emerged from studies 
based on the use of fluorescent fusion proteins. An obvious extension of this technique 
would be to develop systems that express tagged non-proteinogenic entities, or those that 
report on enzymatic activities. The realisation that such can not be achieved by standard 
molecular biology techniques alone has led to a shift of attention towards organic 
chemistry-based approaches. In principle, the use of synthetic tags is not limited to a 
particular class of biomolecules and, moreover, the variety in the nature of the tag is only 
limited by the imagination of the researcher. In addition, proper design of the synthetic tag 
enables not only monitoring of the presence or absence of the tagged biomolecule in a 
specific system (as with GFP approaches), but will also provide information about enzyme 
activity or about the cellular fate of a metabolite of any given class of biomolecules. 
Most biochemical studies are executed in cell lysates, since these are generally 
easier to exploit experimentally as compared to whole cells or animal models. In line with 
this, chemical tagging of a biomolecule in a cell lysate obviates the need for the tag to be 
cell permeable. Reporter entities, such as biotin, fluorescent labels and radiolabels, may 
therefore be incorporated into the molecular probes liberally, as long as they do not 
interfere with the process of interest. However, because of intrinsic disadvantages of 
working with cell lysates (dilution factor, pH change, loss of subcellular 
compartmentalisation), live cell systems are preferred where possible. 
Tagging biomolecules in living cells does, however, impose some important 
restrictions on the design of the chemical tags. For instance, the cell-impermeability or the 
reduced profiling potency4 of many biotinylated constructs essentially precludes the direct 
incorporation of biotin in a molecular probe. To a lesser extent, the same also holds true for 
many radiolabels and fluorescent tags. It is therefore not surprising that in recent years a 
variety of two-step labeling strategies have been developed.5 These strategies are based on 
a) introduction of a bioorthogonal6 attachment site to a biomolecule in a living cell system, 
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and b) addition of the reporter 
moiety, through a chemoselective 
ligation, to the attachment site at a 
desirable stage in the experiment. 
Three different approaches for 
introducing the bioorthogonal entity 
into the biomolecule(s) of choice 
and attaining the chemoselective 
ligation with a tagging or 
crosslinking agent can be discerned 
(see Figure 1): 
A. Treatment of tissue with a 
chemically modified metabolic 
precursor will lead to incorporation 
of a bioorthogonal attachment site 
in the target biomolecules. 
Subsequently, the attachment site is addressed in a chemoselective ligation. Examples of 
this strategy include the introduction of bioorthogonally functionalised amino acids into the 
cell's protein synthesis machinery7 and the introduction of other modified precursors of 
biomolecules into post-translational modifications and oligosaccharide clusters.8 
B. Creation of mutant cell lines expressing fusion proteins with attachment functionalities 
that specifically react with a complementary synthetic probe of choice.9 
C. Tagging of enzymes with small functionalised active site directed probes in living cells, 
then addressing the functionality in a bioorthogonal chemical ligation step.10 
A. Use of chemically modified metabolic precursors 
Methionine tRNA-synthetase is able to accept unnatural methionine isosteres as 
substrates.11 Using this feature, Van Hest et al. succeeded in introducing amino acids with 
unsaturated side chains (for instance, 2-amino-5-hexynoic acid) into proteins.12 In a joint 
effort of the Tirrell and Bertozzi groups, this approach was used for the decoration of E. 
coli proteins with azide residues.13 Addition of azidohomoalanine (1, see Figure 2) to a 
Figure 1. Three different strategies for the labeling of 
biomolecules in living cells: A) introduction of a 
chemically modified metabolic precursor, then 
addressing the modification; B) creation of fusion 
proteins with a bioorthogonal attachment site, 
followed by ligation in vivo; C) in vivo tagging of 
enzymes with activity-based probes, then ligation 
with a reporter molecule. 
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methionine-depleted bacterial culture resulted in the incorporation of azide moieties instead 
of methionine residues. After cell lysis, the azide functionalities were addressed 
chemoselectively by a modified Staudinger reaction (also referred to as the Staudinger-
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Figure 2. Some bioorthogonally functionalised amino acids that have been built into proteins via the 
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Scheme 1. Staudinger-Bertozzi ligation to connect R1  and R2. 
Using the same technique for the construction of modified 
proteins, Tirrell and co-workers reported that azide-decorated cell 
surface proteins can be labeled using a copper catalyzed Huisgen-type 
[3+2] cycloaddition (see Scheme 2).14 This reaction, that can be 
executed under aqueous conditions, and that features two reactive 
components that are largely inert in physiological environments, was 
developed independently by the groups of Meldal15 and Sharpless.16 A 
biotin propargyl amide was used to address the cell surface azides by 
use of this cycloaddition reaction. After staining with fluorescent 
avidin, the biotin-modified cells were easily distinguished from the 
non-modified cells. 
Schultz and co-workers have embarked on the development of 
genetically engineered micro-organisms that encode for non-natural 
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altered micro-organisms that 
endogenously synthesise a 
21st amino acid with any 
desirable functionality. This 
amino acid residue is 
recognised by a novel tRNA 
synthetase that subsequently 
transfers it to a tRNA 
equipped with a unique 
anticodon, allowing site-
specific incorporation of the 
amino acid in selected 
proteins. The current state of 
the art dictates that bioorthogonally functionalised amino acids for incorporation still need 
to be added to the growth medium of altered organisms.18 For example, proteins with either 
p-azidophenylalanine (2, Figure 2) or O-propargyltyrosine (3)19 as unnatural amino acid, 
depending on the composition of the growth medium, were expressed in genetically 
modified yeast. After affinity purification of the target proteins, both modifications were 
addressed by their fluorescent counterparts (that is, azide- or alkyne-functionalised dansyl 
or fluorescein derivatives) in a Huisgen-type cycloaddition. This procedure allowed for in-
gel visualisation of the modified target proteins. The authors are currently investigating an 
in vivo labeling strategy based on the same principles. 
A major breakthrough in protein engineering is the development of techniques that 
allow the incorporation, at a predesigned site, of non-natural amino acids that are highly 
reactive under photolytic conditions.20 After exposure to UV light, the resulting 
intermediates, normally being carbenes or nitrenes, will react with surrounding 
functionalities, including amide linkages. Crosslinking may occur with surrounding 
proteins, thereby providing information on protein-protein interactions. Until recently, 
however, the site-specific incorporation of desired amino acids could only be achieved in in 
vitro translation systems and with low efficiency. Further, the application of the modified 
proteins obtained through in vitro translation met with considerable technical difficulties. 
The in vivo translation system developed by the group of Schultz opens the way to many 
Figure 3. Introduction of a photocrosslinker amino acid (4) 
specifically into GST of E. coli, followed by irradiation with UV 
light leads to crosslinked GST molecules, thereby confirming 
that GST exists as dimers in vivo. 
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exciting applications, in which protein-protein interactions can be monitored in the proper 
environment of the living cell. 
A relevant example of this strategy entails the following set of experiments.21 
Azidophenylalanine was incorporated at the binding surface of glutathione S-transferase 
(GST) in the appropriate E. coli mutant, and the protein was purified through its fused His-
tag. Irradiation with UV-light effected crosslinking to another GST molecule. This finding 
indicates that GST occurs in dimers in vitro. In addition, the crosslinking proved to be 
possible in living cells (see Figure 3),22 using a different photocrosslinking amino acid, p-
benzoyl-L-phenylalanine (4). When incorporated at the same site of GST as 
azidophenylalanine, similar results were obtained as in the in vitro crosslinking experiment. 
These results clearly demonstrate the value of the in vivo translation technique for probing 
protein-protein interactions in living cells. 
Transforming micro-organisms such that they incorporate non-natural amino acids 
in selected proteins requires considerable efforts in altering their protein synthesis 
machinery. An alternative strategy for the selective incorporation of bioorthogonal 
attachment sites is represented by adaptation of specific protein post-translational 
modification events. In such a strategy, a key intermediate in a given post-translational 
modification pathway is replaced by a synthetic equivalent containing a ligation handle. 
Successful incorporation now rests on the ability of the involved enzymes to recognise the 
chemically altered metabolic precursor and process it like its natural counterpart, without 
interfering with the incorporated ligation functionality. 
Seminal work by Bertozzi and co-workers on the latent labeling of cell surface 
glycoproteins comprises one of the hallmarks of contemporary chemical biology research.23 
It was demonstrated that a synthetic N-acetylmannosamine derivative equipped with an 
azide functionality is tolerated by both the sialic acid biosynthetic pathway and the protein 
glycosylation machinery, resulting in the decoration of the cell surface glycoproteins with 
azide-containing sialic acid residues. In short, Jurkat cells were grown on medium 
containing tetra-O-acetyl-N-(azidoacetyl)mannosamine (12, Figure 4) for three days. After 
washing, the cells were treated with phosphine-biotin reagent 14 and subsequently stained 
with fluorescent avidin. In this way, cells fed with 12 could be selectively visualised. This 
result highlights the metabolic stability of the azide group in a living cell, and thereby its 
suitability for use in bioorthogonal chemistry. Recently, the scope of the Staudinger ligation 
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was extended to performing the ligation in 
living animals. Mice were treated with 12 for 
seven days, and the cell surface sialic acid 
residues were addressed by injection of an 
analogue of 14 in which the biotin had been 
replaced with an FLAG-epitope.24 
The modification of specific serine and 
threonine residues in a wide array of 
cytosolic and nuclear proteins with a single 
N-acetylglucosamine residue (Ser/Thr O-
GlcNAc modification) has attracted 
considerable interest in recent years. In many 
cases, the modification appears to be 
reversible and of a highly dynamic nature. 
Further, the finding that this modification 
often occurs at sites also prone to 
phosphorylation has led to speculations that 
protein O-GlcNAcylation, as is the case with 
protein phosphorylation, is involved in the 
control of many biological events. These 
considerations prompted the Bertozzi group25 to establish whether protein O-GlcNAcylation 
could be addressed through selective chemical ligation in a similar fashion as outlined 
above for sialic acid containing glycoproteins. A cell line having a defect in its de novo 
hexosamine synthesis pathway was cultured in the presence of azide-modified GlcNAc 
(compound 13). After cell lysis and isolation of nuclear material, the modified GlcNAc 
moieties were equipped with an affinity label using the Staudinger-Bertozzi ligation. As a 
result, the authors detected a large number of nuclear proteins that bear the azido-GlcNAc 
modification. 
B. Tagging of fusion proteins with synthetic probes 
The ability to label a protein of choice site-selectively, in order to track its cellular 
localisation and fate, has been the objective of many research efforts in recent decades. 
Fusion proteins containing GFP or its analogues remain the tools of choice for this purpose. 
Figure 4. The structures of azide-modified 
carbohydrates and the use of modified 
ManNAc 12 in cell surface labeling. 
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However, the fact that these proteins are bulky and thereby potentially perturbative, has 
spurred the search for alternatives. Some examples of recent results are described in the 
following section. 
Johnsson and co-workers have developed a labeling strategy that exploits the activity of the 
human DNA repair protein 6-O-alkylguanine-DNA-alkyltransferase (hAGT).26 The 
biological function of hAGT resides in its ability to recognise 6-O-alkylated guanine and 
transfer the alkyl group to one of its cysteine thiols, thereby restoring the structural integrity 
of the DNA. It appeared that hAGT possesses broad substrate specificity with respect to the 
alkyl moiety and, especially, that functionalised benzyl moieties are well tolerated. This 
observation paved the way for the following strategy. A fusion is created between the 
protein of interest and hAGT. In the next step, ligation between the fusion protein and the 
label of choice (biotin, fluorescent or bifunctional tag27) is accomplished by nucleophilic 
attack of hAGT's activated sulfur on the benzylic position of modified guanine derivatives 
(see Scheme 3). It should be noted that special care needs to be taken with mammalian 
cells, since these also express AGT which can react with the 6-O-alkylated guanine, thereby 
causing high background labeling.28 This problem can be avoided by the use of an AGT 
knock-out cell line. Furthermore, the higher activity of AGT-mutants relative to wild-type 
AGT allows selective substoichiometric labeling of AGT fusion proteins.29 The same group 
developed an extension of this approach, in which a chemical inducer of dimerisation 
(methotrexate) was linked to a hAGT-fusion protein, thereby constructing heterodimers of 
proteins that regulate DNA transcription in yeast.30 This method can be regarded as a more 
flexible alternatieve of the GFP method, in the sense that the tag that is transferred to the 
fusion protein of interest can be chosen 
liberally. Although hAGT is 31 amino 
acid residues smaller than GFP and is 
thus expected to cause less perturbation 
of the protein of interest, it is still rather 
bulky. In that sense, it suffers from the 

















Scheme 3. The labeling of hAGT-fusion proteins 
using benzylguanine derivatives.  































Scheme 4. The reaction of N-terminal cysteine engineered proteins with thioester-derivatised 
labels. 
The problem of unwanted cross-reactivity with native proteins, as noted in the 
example above, is circumvented in an elegant approach by the group of Yao,31 who make 
use of the highly selective and biocompatible native chemical ligation reaction of an N-
terminal cysteine and a thioester (Scheme 4). Thus, cell permeable probes containing a 
reporter moiety (label) and a benzyl thioester (18) are reacted with an N-terminal cysteine 
modified target protein overexpressed in E. coli cells. In this way, a highly site-selective 
labeling strategy is attained, without the necessity for knock-out cell lines. It should be 
noted that labeling of internal cysteine residues or other thiols by transesterification is 
highly likely. However, this non-specific labeling will not be observed since under the 
conditions of sample preparation for gel electrophoresis all thioesters will be hydrolysed. 
The advantage of this technique, as compared to the above example, is that the necessary 
modification (only one cysteine residue) is less perturbing in terms of size. However, 
protein engineering still remains a necessity and side reactions on the N-terminal cysteine 
modified proteins may be introduced. 
An exquisite combination of organic chemistry and biochemical engineering is 
represented by the fluorescent labeling strategy developed by Tsien and coworkers.32 The 
toxicity of trivalent arsenic compounds, originating from strong binding to thiol pairs of 
adjacent cysteine residues, inspired the design of novel protein labels. Fluorescent 
biarsenides (exemplified by the so-called FlAsH derivative 21, see Scheme 5) were 
prepared and studied with respect to their binding affinity with synthetic cysteine-
containing oligopeptides. It was found that peptides containing the CCXXCC motive bind 
strongly and selectively to FlAsH. Fusion of the tetracysteine motif to target proteins now 
allows their labeling with FlAsH or its analogues33 at the desired time. The validity of this 
approach was illustrated by the Tsien group in the following experiment.34 Cells were 
generated that express recombinant connexin fused with the tetracysteine tag. Connexins 
are cell surface proteins that establish channels between two aligned cells for exchange of 
subcellular material. Treatment of the culture with the cell-permeable FlAsH compound 
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resulted in selective labeling of clusters of cell surface connexin molecules. At this point, 
an interesting feature of the two-step labeling presented itself. Whereas FlAsH molecules 
bound to recombinant connexins appeared to be relatively stable, excess non-bound FlAsH 
could be readily washed from the culture. Then, treatment with another biarsenic label, 
ReAsH (which colours red as opposed to the green FlAsH), rendered any newly synthesised 
connexin red, while the earlier synthesised connexins remained green. In this way, 
important information on the development of connexin patches was obtained. It is unlikely 
that similar results can be obtained by making use of GFP fusion type constructs. 


















Scheme 5. The reaction of a fusion protein containing a tetracystein motif with the FlAsH reagent 
(21). 
The toxicity and the high background signals arising from FlAsH derivatives as well 
as the cross reactivity as observed in the hAGT-approach are addressed in the approach of 
Nolan.35 The high-affinity interaction between a FKBP12 mutant protein and the synthetic 
ligand, SLF', is exploited to label and inactivate proteins in living cells by fluorophore 
assisted laser inactivation (FALI). Fusion proteins of β-galactosidase and mutant FKBP12 
were expressed in NIH 3T3 cells. The cells were incubated with cell permeable fluorescein 
derivative of SLF', allowing detection of labeled fusion proteins with confocal microscopy. 
In a subsequent FALI-experiment, irradiation of the fluorescein group generated oxygen 
radicals near the galactosidase fusion protein, thereby inactivating the enzyme. This method 
can be used to create spatially and temporally defined enzyme inactivation. 
C. Tagging of enzymes with activity-based probes  
The examples described thus far entail the development of techniques that enable 
the labeling of protein families through the incorporation of selective attachment sites in 
either the polypeptide backbone or in post-translationally added entities. After 
chemoselective ligation of the reporter group, information on both expression levels and the 
Bioorthogonal chemistry in living cells 
 27
localisation of the targeted protein (family) is obtained. Families of enzymatic activities 
provide an alternative strategy for chemoselective attachment of reporter molecules. 
Chemical probes that are designed to bind specifically and irreversibly within the active site 
of a given enzyme, and that are equipped with a reporter molecule, may in principle report 
on both localisation and expression level. Moreover, the fact that binding is dependent on 
actual enzymatic activity introduces a third functional read-out, namely that of proper 
functioning of the targeted enzyme(s). The value of this strategy has been widely 
recognised in recent years, especially in the field of proteolysis.36 In general, short 
oligopeptides that serve as recognition elements for a given protease (family) are equipped 
with both an electrophilic trap (a chemical entity with high reactivity towards the enzyme 
active site) and a reporter group (for instance biotin, fluorescent group, radioisotope). The 
resulting construct is referred to as an activity-based probe (ABP). Treatment of cell lysates 
with an ABP will result in irreversible labeling of the targeted proteases, which can be 
visualised and analysed using standard gel electrophoresis. A distinct advantage of the ABP 
strategy over related strategies that are based on the use of fluorogenic oligopeptide 
substrates is the covalent and irreversible nature. Modified proteases can thereby be 
visualised and, optionally, isolated and identified in a later stage of the experiment, 
facilitating profiling of the enzymatic activities in complex mixtures. ABP labeling of many 
protease families, including serine proteases,37 cysteine proteases (cathepsins,38 caspases39) 
and the proteasome,4 has been reported in recent years. A drawback encountered in these 
procedures, however, is the finding that the presence of the reporter entity generally 
diminishes or even precludes cellular uptake4 of the probes, necessitating cellular lysis prior 
to the labeling experiment. To overcome this shortcoming, several groups have 
endeavoured to introduce small latent ligation sites in ABPs, with the idea that such 
constructs would retain cell permeability. After labeling in living cells, attachment of the 
reporter entity may then be executed ex vivo through a chemoselective ligation reaction. 
This strategy is well illustrated by the recent work of Cravatt and co-workers on the 
profiling of a range of enzyme activities in mammalian tissue cultures (for instance human 
breast cancer glutathione-S-transferase and mouse liver aldehyde dehydrogenase).40 Making 
use of the finding that a diverse range of enzymes are irreversibly disabled by simple 
benzenesulfonyl derivatives, a set of azide containing ABPs were prepared (such as 
compound 23, Figure 5). Cells were incubated with the sulfonate, washed, lysed and the 




































Figure 5. Two-step activity-based enzyme profiling using Huisgen-type cyclisation. 
in a stepwise Huisgen reaction. In a more recent report,41 it was shown that the alkyne 
moiety is not fully bioorthogonal. In a reversed experiment, the ABP was equipped with an 
acetylene moiety and the reporter entity with an azide. It appeared that application of the 
alkyne-functionalysed rhodamine (and therefore an azide-ABP) led to higher background 
labeling than an azide-functionalised rhodamine (with an alkyne ABP). Also, the Cravatt 
group demonstrated the first labeling of proteins in live organisms (mice), and subsequent 
in-gel visualisation of retrieved proteins.40 
Conclusion and perspectives 
The approaches presented all rely on the organic-chemical modification of 
biomolecules (in most cases proteins) in living cells, with the aim to visualise and/or 
retrieve the biomolecules or their metabolites. Application of organic chemistry allows the 
introduction of a multitude of modifications into selected biomolecules. The philosophy 
behind executing the labeling in living cells stems from the desire to trap the targets as 
much in their natural environment as possible, so that artefacts related with cell lysis are 
reduced to a minimum. 
In this sense, it may seem counterintuitive to use molecular biological techniques to 
engineer proteins in such a way as to accommodate a modification. In the examples shown 
in category B (see above), fusion proteins are created, containing an attachment site 
(ranging from a single amino acid - N-terminal Cys - to an entire protein - hAGT). 
Although these modifications are all smaller than GFP, the target protein that is studied is 
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considerably altered compared to its natural counterpart. Further, in the case of the hAGT 
examples, an additional artefact is introduced by the need to knock out the native AGT 
mechanism (in the case of mammalian tissue) in order to diminish background labeling. 
Finally, the creation of fusion proteins for each separate process that one would like to 
study constitutes a tremendous amount of biotechnological effort. However, the collective 
strongpoint of the approaches described in this category is that these are, up to now, the 
only truly in vivo chemical labeling strategies, in the sense that both steps (the tagging and 
ligation) occur in live cells. 
A less invasive strategy is to incorporate, at a designated site of a biomolecule, an 
inconspicuous bioorthogonal modification that can be addressed after the fact (as described 
under category A). Techniques required for altering the protein synthesis machinery in such 
a way that it accepts a non-natural amino acid with a bioorthogonal handle are by no means 
standardised yet. Furthermore, all potential target proteins have to be engineered separately. 
In this respect, the other approach described under A (to feed the cell certain modified 
metabolic precursors that are later expressed in sites of interest) seems less laborious, in the 
sense that non-engineered (wild type) tissues can be studied. Of course, this strategy only 
works if the modified precursors are accepted by the natural metabolic pathway. But with 
the groundbreaking work described in section A, and some careful considerations of the 
modified precursor to be introduced (in terms of site of modification, its size and thereby 
conspicuousness), it is possible to envisage applications in the area of, for instance, lipid 
metabolism and post-translational modifications other than glycanation or glycosidation. In 
fact, the metabolic incorporation of a synthetic azido-farnesyl analogue into farnesylated 
proteins has been shown recently.42 
The third category, the activity-based enzyme profiling approach, is also 
independent of protein engineering. The intrinsic reactivity of native enzymes is exploited 
to a) visualise their activity and b) retrieve the biomolecules from a biological sample. It 
may seem that this strategy can only be applied to enzymatic activities that actually partake, 
through the involvement of an amino acid side chain functionality inherent to the enzyme, 
in the chemical transformation at hand. However, it may well be that, in the near future, 
hydrolytic activities that involve water as the nucleophilic species (rather than a serine- or 
cysteine residue), may be addressed in an ABP fashion, for instance through the application 
of well-designed suicide substrates. 
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In the field of activity based profiling, there are many areas still to be developed. 
Firstly, all studies done so far in the area of activity-based profiling have been on the 
qualitative level (whether a labeled protein can be detected or not). Not much effort has 
been devoted to efficacy studies of both the tagging and the subsequent ligation step, in 
terms of side reactions, molar yield and kinetics. Of course, this requires robust analytical 
methods for the characterisation of the tagging and ligation products. With detailed 
information in this area in hand, it will be possible to advance the in vivo labeling strategy 
to a truly quantitative approach, in which the levels of certain enzymatic activities can be 
compared between, for instance, diseased and control tissues. One can readily imagine a 
merge of activity based profiling of enzymatic activities with the isotope-encoded affinity 
probe techniques developed by Aebersold and coworkers.43 In such a strategy, tissue from 
different sources would be treated with a pair of ABPs differing only in 
hydrogen/deuterium content. 
There is much to be gained from studies on enzymatic activities other than 
proteases, which up to now have been the subject of in vivo ABP-based techniques. With 
the advances made in the design and synthesis of irreversible inhibitors for other enzymes 
(for instance glycosidases and phosphatases), it is now possible to embark on similar in vivo 
strategies with these enzymes. The first step toward in vivo activity based profiling of 
glycosidases has been made by the Bertozzi group. A known mechanism-based glycosidase 
inhibitor was equipped with an azide moiety and used to profile enzyme activity in cell 
lysates.44 
A last, but certainly not least, perspective on strategy C entails the approach best 
described as forward chemical genomics.45 This entails the incubation of a certain tissue 
with a label of choice, followed by the ligation reaction, retrieval and identification of the 
products. This may lead to the discovery of enzymatic activities or metabolites that may not 
have been envisaged or have been overlooked, because they are, for instance, not present in 
cell lysates.  
It can be concluded from the examples described in this chapter that the labeling of 
proteins in living cells using bioorthogonal organic chemistry is an effective and reliable 
approach with high potential for further application. Although the described approaches 
which employ organic chemistry, rather than biotechnology, are only just past the stage of 
proof-of-principle, it is obvious that there is a considerable interest from both the organic 
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chemistry, biology and medical research communities. It is therefore only a matter of time 
before these techniques will find acceptance and applicability in fundamental biochemistry, 
pharmaceutics and medicine. 
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Detection of active proteasomes by a two-




Major efforts in unraveling of the human genome and the genetic material of most 
relevant human pathogens, enabled the focus in biomedical and biological sciences to shift 
towards the global assessment of expression levels and function of the gene products. The 
reason for the renewed interest in protein activity is obvious: biological processes are 
modulated at the protein level in health and disease. Approaches that report on transcription 
levels are not informative for the levels of activities of the products encoded by these 
transcripts. Equally important, the relevant activities are those in living cells and not what is 
measured in vitro. At the same time, the global assessment of highly complex and dynamic 
protein mixtures, as found in intact cells, is a much more arduous task than that of the 
relatively static genome. This holds true especially when aiming for insight in the activity 
of proteins rather than for their expression levels. 
Chemistry-based functional proteomics approaches2,3 have been developed based on 
the use of synthetic compounds that modify a selected subset of proteins covalently and 
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irreversibly. These methodologies combine the attractive features of simplifying the 
complex proteome by selecting protein families on the basis of their function.4 For instance, 
broad-spectrum, irreversible protease inhibitors have been used in the profiling of serine 
proteases,5 cysteine proteases,6 and the catalytically active subunits of the proteasome.7,8 
These inhibitors are equipped with either a radioisotope, a biotin moiety or a fluorescent 
tag, to allow respectively visualization, isolation and quantification of the proteases. The 
cell-impermeability of the compounds used in these examples limits their use to in vitro 
applications and this limitation is an unavoidable consequence of the use of such probes. 
Two-step labeling strategy 
Here, a new functional proteomics strategy is described, that allows two-step 
labeling of the catalytically active subunits of the proteasome in living cells.9 The 
proteasome is a multi-catalytic protease that accounts for the bulk of cytosolic and nuclear 
proteolysis.10 Previously, a set of extended, peptide-based, irreversible proteasome 
inhibitors have been reported.7 The most potent of these, AdaAhx3L3VS 1 (Figure 1), is 
unique in that it targets all catalytically active β-subunits of both the constitutive- and the 
interferon-γ-inducible immunoproteasome with approximately equal efficiency. Although 



























































Figure 1. Structure of the broad-spectrum cell-permeable proteasome inhibitor 1, the cell-
impermeable radioiodinated derivative 3, and the Staudinger ligation partners 2 and 4 described 
here. 
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Here, it is demonstrated that modification of 1 with an azide 
group (to give 2; Figure 1) neither interferes with its 
inhibitory profile nor with its cell permeability.11 Labeling 
of whole cells with 2 decorates the catalytically active β-
subunits of the proteasome with an azide as a latent ligation 
handle. After cell lysis, retrieval and denaturation of cellular 
protein content, the azido groups can be addressed by the 
biotinylated phosphane reagent 4 in a modified Staudinger 
ligation, as developed by Bertozzi and coworkers (Figure 
2).12,13 
Synthesis 
The synthesis of the azide-containing proteasome 
inhibitor 2 was accomplished as follows (Scheme 1 and 2). 
Treatment of Boc-Lys(Fmoc)-OH (5) with trifluoroacetic 
acid, followed by subjection to diazotransfer conditions 
(TfN3, CuSO4)14 readily afforded (2S)-2-azido-6-(fluorenylmethyloxycarbonylamino)-
hexanoic acid (7; Scheme 1). Standard Fmoc-based solid phase peptide synthesis (SPPS) 
afforded immobilized peptide 8 on acid-labile Wang resin (Scheme 2). Cleavage from the 
resin and solution-phase condensation of carboxylate 9 with leucine vinyl sulfone 1415 
afforded target compound 2 that was 
purified by silica gel chromatography 
(58% overall yield). 
The synthesis of phosphane 
reagent 4 commenced with the 
condensation of Rink amide linker with 
Fmoc-Lys(Mtt)-OH (Scheme 3).16 The 
side chain protective group in 10 was 
removed, followed by condensation 
with biotin to afford immobilized 
biocytin 11. Standard solid phase 
peptide synthesis employing azido acid 
Figure 2. General strategy: 
irreversible proteasome 
inhibition and subsequent 
Staudinger ligation-
mediated biotinylation to 
enable visualization of 


















5 R = NHBoc
6 R = NH2




Scheme 1. Non-standard building blocks used in 
the synthesis of 2 and 4. Reagents and 
conditions: a) 50% TFA/CH2Cl2, 92%; b) TfN3, 
CuSO4, H2O/MeOH, 89%. 
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15,17 Fmoc-aminohexanoic acid and phosphane 16, respectively, followed by acidic 
cleavage from the resin and HPLC purification gave the homogeneous target compound 4 











Scheme 2. Synthesis of azide-containing proteasome inhibitor 2. Reagents and conditions: a) 
Fmoc-Leu-OH, DIC, DMAP, CH2Cl2; b) Repeated cycles of SPPS: Fmoc cleavage: 20% piperidine 
in DMF; amino acid condensation: Fmoc protected amino acid, PyBOP, DiPEA, DMF. Fmoc 
protected amino acids building blocks employed in consecutive order: Fmoc-Leu-OH, Fmoc-Ahx-

























12 R = N3
13 R = NHC(O)(CH2)5NHFmoc
e
Rink Resin-NHFmoc
10 R = Mtt
11 R = biotinyl
c
a, d a, f, g
 
Scheme 3. Synthesis of biotinylated phosphane reagent 4. Reagents and conditions: a) 20% 
piperidine in DMF; b) Fmoc-Lys(Mtt)-OH, PyBOP, DiPEA, DMF; c) 1% TFA/CH2Cl2, then biotin, 
PyBOP, DiPEA, DMF; d) 15, PyBOP, DiPEA, DMF; e) Me3P, 20% H2O/dioxane, then Fmoc-Ahx-
OH, PyBOP, DiPEA, DMF; f) 16, EDC, HOBt, CH2Cl2; g) 50% TFA/CH2Cl2, 16% overall yield. 
Inhibitory results 
In order to establish the inhibition profile of 2, a set of competition experiments was 
performed. The cell line used was EL-4, derived from a murine thymoma. This cell line is 
advantageous because it expresses both the constitutive proteasome and the interferon-γ-
inducible immunoproteasome, containing, in total, 6 distinct catalytically active β-subunits. 
The cell line HeLa, derived from a human cervical carcinoma, was also used. HeLa 
expresses only the constitutive proteasome (3 catalytically active β-subunits). When lysates 
of EL-4 cells were incubated with azide-containing proteasome inhibitor 2 at different 
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concentrations, prior to treatment with radio-iodinated peptide vinyl sulfone 3 (Figure 1), it 
was observed (Figure 3A) that labeling of the six individual subunits was abolished at final 
inhibitor concentrations of 10-30 µM, demonstrating 2 to be a proteasome inhibitor of equal 
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Figure 3. a) Cell lysate prepared from EL-4 cells was incubated with 2 at concentrations ranging 
from 0 to 30 µM. Residual unmodified subunits were labeled by subsequent incubation with 
radioiodinated inhibitor 3. Labeled subunits were resolved by SDS-PAGE and visualized by 
autoradiography. b) Ub-R-GFP accumulates when proteasomal degradation is blocked. Cells were 
incubated either with a solvent control or 2 (50 µM final concentration) for 8 hours and fixed, 
followed by blue nuclear staining of the DNA with DAPI (blue). Confocal laser scanning microscopy 
revealed 2 to be a cell-permeable proteasome inhibitor. c) Lysates from EL-4 and HeLa were 
reacted with 2 at 37˚C for one hour and then boiled in the presence of SDS, to achieve protein 
denaturation and exposure of the azido moieties of conjugated 2. The azido moieties were 
biotinylated via a Staudinger ligation by adding an aqueous solution of reagent 4 to the reaction 
mixture, followed by incubation for 1 h at 37˚C. Samples were separated by SDS-PAGE and 
transferred to polyvinylidene difluoride membrane. Incubation with streptavidin-horseradish 




was determined with the following procedure: U373 cells expressing a green fluorescent 
protein (GFP)-ubiquitin fusion protein18 (Ub-R-GFP) were treated with compound 2 at 50 
µM (final concentration) and compared with untreated cells for the presence of GFP 
fluorescence. Ub-R-GFP is rapidly degraded by the proteasome with little green 
fluorescence at steady state as a result (Figure 3B). However, in cells treated with 2, a time-
dependent accumulation of fluorescence was observed, demonstrating the capacity of 2 to 
inactivate the proteasome in living cells. 
Labeling of active proteasomes 
Encouraged by these results, the suitability of a Staudinger ligation was established 
for two-step visualization of catalytically active proteasome subunits in cell lysates as well 
as in living cells. In the first experiment, cell lysates from EL-4 and HELA cells were 
exposed to 2 at various concentrations, prior to denaturation of cellular protein. The 
resulting mixtures were incubated with biotinylated Staudinger ligation reagent 4 and 
separated by SDS-PAGE. Transfer of the separated protein mixture onto a polyvinylidene 
difluoride (PVDF) membrane, followed by chemiluminescence induced by horseradish 
peroxidase-streptavidin conjugate, resulted in a distinct labeling profile. Labeling intensity 
depended on the dose of 2. The pattern of labeling conforms to that established for radio-
iodinated probe 3.7 Importantly, proteasome derived polypeptides were detected only when 
both inhibitor 2 and Staudinger reagent 4 were used (Figure 3C, lanes 4-7 and 9-12). These 
results establish the selectivity of 4 in complex physiological mixtures to target only those 
proteins modified with an azide functionality. 
Next, the possibility of covalent 
proteasome inhibition in living cells 
followed by post-lysis Staudinger 
ligation and immunoblotting was 
investigated. EL-4 cells were incubated 
overnight with 2 (Figure 4). Subsequent 
glass bead lysis, incubation with 4, 
ensuing SDS-PAGE separation and 
Western blotting afforded a labeling 








1          2           3          4 
2(µM) 0          2         10       50
Figure 4. Proteasome labeling in living cells. 
Incubation of living cells (5 × 106 at 37°C) with 2 
followed by post-lysis ligation and 
immunoblotting reveals the active proteasomal 
content and composition in living cells. 
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that obtained for labeling of cell lysates (Figure 3C). Importantly, in vivo labeling appeared 
to be more effective (compare Figure 4 with Figure 3C), indicating a more efficient 
targeting of all proteasomal subunits in living cells as compared to the labeling patterns 
obtained in vitro. The latter observation is possibly due to partial dissociation of the 
proteasome particle during cell lysis and storage. It was concluded that inhibitor 2 can be 
used in combination with biotinylation reagent 4 for the visualization of active proteasomes 
in living cells. 
Conclusions 
In summary, we have presented a novel strategy to visualize active enzymes in 
living cells. Compound 2 was identified as a powerful, cell-permeable inhibitor of all 
proteasomal activities, and 2 can subsequently be addressed by post-lysis labeling via a 
chemoselective Staudinger ligation. This protocol opens the way towards the screening, in 
living cells, of proteasomal activity in, for example, human tissue samples. 
The measurement of proteasome activity in live cells remains an important goal, not 
only in the context of novel treatment strategies for cancer, but also in biological systems 
more generally. For instance, malfunctioning of the ubiquitin-proteasome system has been 
implicated in both cancer19 and neurodegeneration.20 
Importantly, the two-step methodology (this is, covalent, irreversible enzyme 
modification followed by chemoselective modification) may be extended towards the 
development of novel chemoselective ligation partners compatible with desired cellular 
environments. The application of this strategy for the assessment of the activity of other 
protease enzyme activities in living cells is further elaborated in chapter 3. 
Experimental section 
General methods and materials: Solvents used in the solid phase peptide synthesis, DiPEA and 
TFA were all of peptide synthesis grade (Biosolve) and used as received. The protected amino 
acids, Wang resin (0.86 mmol/g), Rink amide MBHA resin (0.78 mmol/g) and PyBOP were 
obtained from NovaBiochem. Fmoc-Lys(Mtt)-OH was from Senn Chemicals, EDC and DIC from 
Acros and anhydrous HOBt from Neosystem. Adamantane acetic acid was purchased from Aldrich. 
Leucine vinyl sulfone was prepared as reported.15 SPPS was carried out using a 180° Variable Rate 
Flask Shaker (St. John Associates, Inc.). LC/MS analysis was performed on a Jasco HPLC system 
(detection simultaneously at 214 and 254 nm) coupled to a Perkin Elmer Sciex API 165 mass 
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spectrometer equipped with a custom-made Electrospray Interface (ESI). An analytical Alltima C18 
column (Alltech, 4.6 × 250 mm, 5 µm particle size) was used. Buffers: A = H2O; B = CH3CN; C = 
0.5% aq. TFA. For RP HPLC-purification of 2 and 4 a Biocad “Vision” automated HPLC system 
(PerSeptive Biosystems, Inc.) was used. 1H-NMR and 13C-NMR spectra were recorded with a 
Bruker AC200 instrument at 200 and 50.1 MHz, respectively. 
Solid phase peptide synthesis: Where appropriate removal of the Fmoc protecting group was 
accomplished by treatment of the resin-bound peptide with 20% (v/v) piperidine in DMF for 20 
min. Peptide coupling steps were performed by treatment of the resin with a premixed (5 min) 
solution of the of the appropriate acid (5 eq.), PyBOP (5 eq.) and DiPEA (6 eq.) in DMF for 1 h. 
Coupling efficiencies were monitored with the Kaiser test and couplings were repeated if necessary. 
After coupling and deprotecting steps the resin was washed with DMF (5×). 
Synthesis of Fmoc-Ahx(α-N3)-OH (7): Boc-Lys(Fmoc)-OH (2.0 g, 4.2 mmol) was treated with 
TFA/CH2Cl2 (20 ml, 1/1 v/v) for 40 minutes. Solvents were removed in vacuo yielding 1.9 g (3.9 
mmol, 92%) of crude TFA-salt of H-Lys(Fmoc)-OH 6. The crude product was treated with 
trifluoromethanesulfonyl azide as described14 followed by a modified work-up procedure. After 
removal of the organic solvents, the aqueous slurry was acidified with 1 N HCl to pH 2 and 
extracted with EtOAc (4×). The combined organic phases were dried over MgSO4, filtered and 
concentrated in vacuo. Purification of the crude product over silica gel (hexanes/EtOAc 2/1 v/v) 
yielded 1.4 g (3.5 mmol, 89%) of a white foam. 1H NMR (200 MHz, CDCl3, 25°C, TMS): δ= 7.75 
(d, 3J (H,H)=7.3 Hz, 2H; ArH), 7.57 (d, 3J (H,H)=7.3 Hz, 2H; ArH), 7.40-7.25 (m, 4H; ArH), 4.41 
(d, 3J (H,H)=6.6 Hz, 2H; CHCH2O), 4.19 (t, 3J (H,H)=6.6 Hz, 1H; CHCH2O), 3.92 (t, 3J (H,H)=6.7 
Hz, 1H; αCH), 3.18 (m, 2H; εCH2), 1.7-1.3 ppm (m, 6H; βCH2, γCH2, δCH2); 13C NMR (50.1 MHz, 
CDCl3, 25°C, TMS): δ=174.1, 156.8, 143.5, 140.9, 127.1, 126.7, 124.6, 119.6, 66.4, 62.1, 60.4, 
46.7, 30.6, 28.8, 22.4 ppm; ESI-MS: m/z (%) = 417.2 (100) [M+Na+], 811.5 (20) [2M+Na+]. 
Synthesis of 2: Wang resin (1.0 g, 0.86 mmol) was condensed with Fmoc-Leu-OH (1.2 g, 3.4 
mmol) in CH2Cl2 (25 ml) under the agency of DIC (0.54 ml, 3.44 mmol) and a catalytic amount of 
4-(dimethylamino)pyridine for 2 h. The resin was filtered off, washed (3× CH2Cl2-MeOH, CH2Cl2 
and Et2O), and air-dried. Loading was determined by quantification (UV) of Fmoc cleavage, and 
proved to be 0.66 mmol/g. The resin, 260 mg (0.17 mmol) was elongated using standard Fmoc-
based SPPS to give resin-bound AdaAhx(α-N3)Ahx2Leu2-OH. Treatment of the immobilized 
peptide with TFA/H2O (95/5 v/v) for 1 h, filtration and removal of solvent in vacuo was followed 
by a solution phase block coupling with leucine vinyl sulfone TFA salt 14 (1 eq.) under the agency 
of HBTU (1 eq.) and DiPEA (2.2 eq.) in DMF (1.5 ml). After evaporation of the solvent, the residue 
was dissolved in EtOAc. The product was precipitated by sonication. The precipitate was filtered 
and washed with EtOAc, Et2O and hexanes to yield 146 mg (0.15 mmol, 88%) of the title 
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compound in 90% purity as judged by LMCS. Silica gel purification (0-10% MeOH in EtOAc) of 
21 mg (22 µmol) of the crude product yielded 14 mg (14 µmol) of the title compound (58% overall 
yield) ready to use in biological experiments. LC/MS: m/z = 974.9 [M+H+]. 
Synthesis of 4: Fmoc Rink amide resin (128 mg, 100 µmol) was deprotected as described. Fmoc-
Lys(Mtt)-OH (0.5 mmol, 312 mg) was coupled. The Mtt protecting group was removed by 
treatment of the resin with 1% TFA in CH2Cl2 for 0.5 min.16 This treatment was repeated 9 times 
until no more yellow color was observed in the eluted solution. The resin was neutralized with 10% 
DiPEA in DMF. Biotin (0.5 mmol, 122 mg) was coupled under the agency of PyBOP (1 eq.) and 
DiPEA (1.2 eq.) in DMF. After removal of the Fmoc group, the resulting free amine was condensed 
with 1517 (0.5 mmol, 237 mg). After washing of the immobilized peptide with dioxane (3×), the 
azide moiety was reduced by treatment with Me3P (0.6 ml of a 1 M solution in toluene, 0.6 mmol, 6 
eq.) in dioxane/water (2 ml, 4/1 v/v) for 40 min14 followed by dioxane washes (3×), and Fmoc-Ahx-
OH (0.5 mmol, 180 mg) was coupled. Of the obtained resin, 50 µmol was treated with piperidine as 
described above to remove the Fmoc protecting group and the resin was then washed with CH2Cl2 
(3×). Phosphane 16 (90 mg, 0.25 mmol) was activated with EDC (48 mg, 0.25 mmol) and HOBt 
(41 mg, 0.3 mmol) in CH2Cl2 (2 ml) under an argon atmosphere for 5 min, and subsequently added 
to the resin. The resin was agitated under argon atmosphere for 1 h, and the resin was washed 
(CH2Cl2, then DMF-MeOH alternating (3×), CH2Cl2-MeOH alternating (3×), and CH2Cl2), while 
keeping the resin under argon atmosphere. The immobilized peptide was liberated from the resin by 
treatment with TFA/CH2Cl2 (1/1 v/v) for 1 h. Evaporation of the solvents in vacuo followed by 
HPLC-purification of the crude product (linear gradient in B: 25-55% B in 3 column volumes) 
yielded 8.0 mg (8 µmol, 16%) of a white solid. LC/MS: calculated = 1020 [M+H+], found = 1020 
[M+H+]. The product was kept as aliquots of a stock solution (1.6 mM) in degassed DMSO at –
80°C. 
Proteasome labeling in living cells: EL-4 cells, cultured in RPMI (Gibco, Invitrogen Corp.) 
supplemented with L-glutamine, fetal calf serum, penicillin and streptomycin were incubated 
overnight with concentrations of inhibitor 2 as indicated in Figure 3. Cells were harvested by 
centrifugation. After glass-bead lysis, 10 µg of protein in 33 µl of lysis buffer (50 mM Tris, 5 mM 
MgCl2, 0.5 mM EDTA, 0.25 mM Sucrose, pH 7.4) was denatured by the addition of 2 µl of 20% 
SDS followed by brief boiling. The denatured sample was further incubated with 10 µl of 4 (100 
µM) in DMSO/CH3CN/H2O (6/1/1 v/v/v) for 1 h at 37°C. Without further heating 4× sample buffer 
was added and samples were run on either a 12.5% or 15% SDS-PAGE gel followed by transfer to 
PVDF membrane. The membrane was blocked with milk and washed briefly with PBS containing 
1% TWEEN-20 (Sigma) (3×) and incubated with streptavidin-HRP (Amersham Life Sciences, 
Chapter 2 
 44
dilution 1: 10.000) for 1 h at ambient temperature. The membrane was washed as before and soaked 
in Western Lightning Chemiluminescence (Perkin Elmer) reagent followed by developing a film. 
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A cell-permeable inhibitor and activity 





The proteasome is a multi-catalytic protease that degrades the majority of cytosolic 
and nuclear proteins to oligopeptides.2 This degradation is a highly regulated process, and a 
small portion of the oligopeptides produced escape further degradation and are loaded on 
MHC class I molecules for presentation to the immune system.3 Proteasomal protein 
degradation takes place in a barrel shaped structure that consists of four rings of seven 
subunits each. Three of the β subunits in the middle two rings, β1, β2 and β5, display 
protease activity. Each catalytic subunit has a different substrate specificity. The β1 subunit 
cleaves preferentially after acidic residues and is therefore referred to as the caspase-like 
subunit. The β2 subunit has a preference for peptide bond cleavage after basic residues and 
is responsible for the trypsin-like activity. The β5 subunit displays a chymotrypsin-like 
activity and cleaves after large, hydrophobic residues. In the interferon-γ-inducible 
immunoproteasome, the catalytic β1, β2 and β5 subunits are replaced by the β1i, β2i and 
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β5i immunosubunits. The immunosubunits display a substrate specificity slightly different 
from to that of the respective constitutive subunits. As a result, the immunoproteasome and 
proteasome generate a different spectrum of oligopeptides from the same protein, which 
effects a different spectrum of antigens presented on MHC class I molecules.4 
Inhibitor design 
To gain more insight in the role of the different proteasomal subunits in the process 
of protein degradation and antigen presentation, it would be highly useful to have tools to 
switch off one of the proteasome activities selectively. Some inhibitors with selectivity for 
either the trypsin-like or the chymotrypsin-like subunits have been reported.5 In contrast, no 
cell-permeable selective inhibitor or activity based probe for the caspase-like proteasomal 
subunits has been reported to date. In order to develop such tools, precedents from the 
literature were used to select an appropriate recognition sequence and electrophilic trap. In 
this respect, it appeared that the selective reversible inhibitor 1 (Figure 1) of the caspase-
like subunit of the proteasome was a suitable starting point for the development of an 
irreversible inhibitor.6 Furthermore, it has been shown before that vinyl sulfones are 
suitable electrophilic traps to alkylate the N-terminal threonine residue, the active site 
nucleophile of the proteasome. The ability of vinyl sulfones to alkylate proteasomal 
catalytic residues depends on the 
functional group downstream of the vinyl 
sulfone moiety. For example, Bogyo and 
coworkers showed that in case of GL3-
vinyl sulfone, phenolic vinyl sulfone (2; 
Figure 1) was a better inhibitor of the 
caspase-like site than the corresponding 
methyl vinyl sulfone (3; Figure 1).7 
Thus, a phenolic vinyl sulfone seemed to 
be the obvious electrophilic trap to be 
employed. 
To avoid the elaborate synthesis 
of a suitably protected aspartic acid vinyl 
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Figure 1. Relevant reversible and irreversible 
proteasome inhibitors. 
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for block coupling of the peptide vinyl sulfone building block to a peptide sequence, the P1 
aspartic acid was replaced by leucine, thus generating inhibitor 4 (Figure 1). It is known 
that the caspase-like subunit also cleaves after hydrophobic branched chain amino 
acids,6,8,9,10 and this concept has been used in irreversible inhibitor design. An epoxyketone 
based inhibitor with leucine in the P1 position can inhibit the caspase-like subunit with 
significant, albeit not absolute, specificity.11 Furthermore, the leucine residue renders the 
inhibitor more apolar and thus possibly better cell-permeable. 
In order to convert inhibitor 4 into an activity probe for the caspase-like subunit of 
the proteasome, an azide moiety was introduced on the N-terminal acetyl function to give 4 
(Figure 1). In Chapter 2 of this thesis, an approach employing the Staudinger ligation to 
biotinylate proteasome modified with an azide-containing probe in a two-step labeling 
fashion is described. Based on literature evidence,12 direct attachment of a biotin moiety to 
the probe was expected to influence both cell permeability and subunit specificity. 
Here, the first highly specific, cell-permeable inhibitors of the caspase-like activities 
of the proteasome (4 and 5; Figure 1) are presented. At low concentrations, these 
compounds show selectivity towards the caspase-like subunit of the immunoproteasome in 
favour of the corresponding caspase-like activity of the constitutive proteasome. Activity 
probe 5 allows two step labeling of active caspase-like subunits of the immunoproteasome 
and, at higher concentrations, of the constitutive proteasome. Labeled subunits can then be 
visualized via post-lysis ligation and Western blotting. 
Synthesis 
The synthesis of inhibitor 4 started with the synthesis of tripeptide 6 on acid-labile 
Wang resin (Scheme 1). Acidolysis of the peptide from the resin and subsequent solution 
phase condensation with vinyl sulfone 87 afforded the target compound in 45% overall 
yield after RP-HPLC purification. The synthesis of activity probe 5 was accomplished in a 
similar fashion. Azide-functionalized peptide 7 was synthesized on Wang resin. Cleavage 
of the peptide from the solid support and coupling to 8 gave target compound 5 in 12% 
yield after RP-HPLC purification. 
For the Staudinger ligation, new biotinylation agent 12 (Scheme 2) was designed. 
The relatively facile synthesis of 12, as well as the possibility of purification using silica gel 
chromatography, allow for production of larger amounts than the comparable reagent 
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presented in Chapter 3. The synthesis starts with biotinylation of monoprotected bisamine 9 
using a standard peptide coupling method. After removal of the Boc protecting group with 
5% water in TFA, the liberated amine functionality was acylated with phosphane 13.13 Both 
the use of the EDC/HOBt system to activate the acid moiety and a protective argon 
atmosphere proved necessary to suppress premature oxidation of phosphane 12 to the 
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Scheme 1. Synthesis of inhibitor 4 and activity probe 5. Reagents and conditions: a) Fmoc-Nle-OH, 
DIC, DMAP, CH2Cl2; b) Repeated cycles of SPPS: Fmoc cleavage: 20% piperidine in DMF; amino 
acid condensation: Fmoc protected amino acid, HCTU, DiPEA, NMP. Fmoc protected amino acid 
building blocks employed in consecutive order: Fmoc-Pro-OH, Fmoc-Ala-OH, acetic anhydride or 
azidoacetic acid; c) TFA/H2O (95/5 v/v); d) 8, HATU, DiPEA, DMF, overall yield 18% and 26% for 4 
























9: R1 = Boc, R2 = H
10: R1 = Boc, R2 = Biotinyl











Scheme 2. Synthesis of Staudinger-reagent 12. Reagents and conditions: a) biotin, HCTU, DiPEA, 
DMF; b) TFA/H2O (95/5 v/v), 56% yield over two steps; c) 13, HOBt, EDC, DiPEA, CH2Cl2, argon 
atmosphere, 22% yield.
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Evaluation of inhibitory activity 
The subunit specificity of newly synthesized inhibitor 4 was determined as follows. 
Purified rabbit muscle 26S proteasome was incubated in the presence or absence of 50 µM 
inhibitor, and aliquots of the mixture were assayed with fluorogenic substrates for the 
respective active site. The effect of the inhibitor on the proteasomal activity was determined 
by relative fluorescence in the presence or absence of inhibitor.14 Figure 2 shows that 4 
selectively blocks the caspase-like site of the proteasome. Furthermore, an increased 
activity of the trypsin-like site is observed. 
 
Figure 2. Protease assay with purified proteasome shows specificity of 4 for the caspase-like site of 
the proteasome. Proteasome was incubated with 50 µM inhibitor and protease activity was 
measured by the amount of fluorescence generated by degradation of 7-amido-4-methylcoumarin 
(amc) substrates for the three proteasomal subunits. Suc-LLVY-amc was used for the 
chymotrypsin-like site, Ac-nLPnLD-amc for the caspase-like site and Ac-RLR-amc for the trypsin-
like site. 
Next, the effects of compound 4 and 5 on proteasomes in cultured cells were 
measured. Mouse T-cell lymphoma EL-4 cells, human multiple myelome RMPI8226 cells 
and human immortalized B-lymphocytes (LG2 clone) were incubated for 16 h with 
different concentrations of inhibitors 4 and 5. Cytosol was squeezed out of digitonin-
permeabilized cells by centrifugation, and the activity of all three types of active sites was 























































































































































Figure 3. Protease activity measured in cell extracts after 
treatment with inhibitor 4 (a,c,e) or 5 (b,d,f). EL-4 cells 
(a,b), RPMI 8226 cells (c,d) and LG2 cells (e,f) were 
incubated 16-18 h with a concentration range of 4 or 5. 
Cells were lysed, and remaining proteasomal activity was 
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EL-4 cells (Figure 3a) show a plateau at 50% inhibition of the caspase-like activity. As EL-
4 cells express both proteasome and immunoproteasome in equal amounts, this could 
indicate that 4 targets only one of the caspase-like sites. Also, the trypsin-like activity is 
increased over two-fold, indicating allosteric activation or an increase in proteasome 
expression due to inhibition of the caspase-like site. In RMPI cells, a plateau in caspase-like 
activity occurs between 10 and 20 µM 4 (Figure 3c), and at higher concentrations all 
caspase-like subunits can be blocked. In this cell type, no activation of the trypsin-like site 
is observed. Inhibitor 5 is less potent in these cells and does not show a plateau (Figure 3d), 
but some activation of the other subunits is observed. In LG2 cells (Figure 3e and 3f), 
inhibitor 4 shows a plateau around 10 µM, and at higher concentrations activation of the 
trypsin-like activity occurs. Azide-containing inhibitor 5 shows a plateau at higher 
concentrations, and less activation of the other subunits. 
Labeling of caspase-like subunits 
In order to visualize the subunits that are modified by inhibitor 5, the azide moieties 
of labeled proteasomal subunits were modified with a biotin moiety by Staudinger ligation 
with biotinylated phosphane 12. In short, cells were incubated for 16 h with different 
concentrations of 5, permeabilized with digitonin, and cytosol was squeezed out by 
centrifugation, followed by extraction of organellar proteins by sonication. Both extracts 
were treated with phosphane 12 to introduce a biotin moiety, separated on SDS-PAGE and 
transferred onto PVDF membranes. Biotinylated proteins were visualized using a 
streptavidin-IRdye 800CW conjugate (Figure 4). In all cell lines, at lower concentration 
only β1i is modified, whereas at higher concentration of 5, both caspase-like subunits (β1 
and β1i) are targeted. The lack of labeling of the other proteasomal subunits confirms the 
specificity for 5 for the caspase-like site as found in the fluorogenic peptidase assays 
described above.  
Because the proteasomal subunits are not always resolved on SDS-PAGE, a 2D 
separation was performed, which is known to separate all catalytic active proteasomal 
subunits. Cells were incubated with 40 µM and 80 µM of inhibitor 5. Cytosolic extracts 
were prepared as described above, incubated with phosphane 12 and separated on a 2D gel 





Figure 4. Two-step visualization of targets of compound 5. EL-4 cells, RPMI 8226 cells and LG2 
cells were incubated 16-18 h with different concentrations of 5. Cells were permeabilized with 
digitonin, allowing separation of the cytosolic fraction from the organellar fraction. Both were treated 
with biotinylated phosphane 12, followed by fractionation on SDS-PAGE and Western blotting. 
Labeled proteins were visualized by streptavidin-IRdye800CW. 
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Figure 5. 2D SDS-PAGE of cytosilic extracts of labeled EL-4 cells treated with 10 µM (a) and 80 µM 
(b) 5. Extracts were generated and treated as before, and separated by 2D gel electrophoresis. 
Proteins were stained with streptavidin-IRdye800CW indicating that only the caspase-like activities 
of the immunoporteasome (β1i) are labeled. 
Conclusions 
Two new vinyl sulfone based proteasome inhibitors are presented here that are 
selective inhibitors of the caspase-like subunits of the proteasome. The uniqueness of these 
reagents is that at lower concentrations they selectively inhibit the caspase-like sites of the 
immunoproteasomes. The introduction of an azide-moiety did not change the inhibition 
profile, and confirmed selective targeting of the caspase-like subunits by visualization via a 
Staudinger ligation followed by and SDS-PAGE and Western blotting. 
Both inhibitors presented here, as well as the Staudinger ligation protocol applied, 
might be of value for future research aimed at the role of the caspase-like subunit in the 
processing of antigens. Furthermore, at lower concentration of inhibitor, the specific 
contribution of the immunoproteasomal caspase-like site in antigen processing can be 
studied. 
Experimental section 
General methods and materials: Solvents used in the solid phase peptide synthesis, DiPEA and 
TFA were all peptide synthesis grade (Biosolve) and used as received. The protected amino acids, 
Wang resin (0.86 mmol/g), and HCTU were obtained from NovaBiochem. SPPS was carried out 
using a 180° Variable Rate Flask Shaker (St. John Associates, Inc.). LC/MS analysis was performed 





Sciex API 165 mass spectrometer equipped with a custom-made Electrospray Interface (ESI). High 
resolution mass spectra were recorded on a Finnigan LTQ-FT (Thermo electron).An analytical 
Alltima C18 column (Alltech, 4.6 × 250 mm, 5 µm particle size) was used. Buffers: A = H2O; B = 
CH3CN; C = 0.5% aq. TFA. For RP HPLC-purifications a Biocad “Vision” automated HPLC 
system (PerSeptive Biosystems, Inc.) was used. The applied buffers were A, B and C. 1H-NMR and 
13C-NMR spectra were recorded with a Bruker AC200 instrument at 200 and 50.1 MHz, 
respectively. 600 MHz 1H-NMR spectra were recorded with a Bruker DMX 600 instrument with 
chemical shifts (δ) relative to tetramethylsilane. TLC analysis was performed on Merck 25DC 
Plastikfolien Kieselgel 60 F254, with detection by UV absorption (254 nm) and spraying with 
KMnO4 (10 g/l in 2% aq Na2CO3). Fluka silica gel (230-400 mesh) was used for column 
chromatography. 
(S)-4-(3-Amino-5-methyl-hex-1-ene-1-sulfonyl)-phenol (8): To a solution of KOtBu (1 g, 8.94 
mmol) and (4-hydroxy-benzenesulfonylmethyl) phosphonic acid diethyl ester (1.5 g, 4.87 mmol) in 
THF was added known Boc-protected leucinal16 (0.92 g, 4.1 mmol). The mixture was stirred for 16 
h, the mixture was diluted with Et2O, washed with sat. aq. NaHCO3 (3×) and sat. aq. NaCl (3×), 
dried (MgSO4), filtered and concentrated in vacuo yielding 1.3 g of crude Boc protected title 
compound. The Boc protecting group was subsequently removed by treatment with TFA/H2O (1 ml, 
95/5 v/v) for 1 h. The reaction mixture was poured into Et2O (50 ml), and the precipitate collected 
yielding 0.45 g, (1.2 mmol, 29% over two steps) of the title compound, which was used without 
further purification. 
N3AcAlaProNle-OH: Wang Resin (2.0 g, 1.7 mmol) was condensed with Fmoc-Nle-OH (4.2 g, 12 
mmol) in CH2Cl2 (30 ml) under the agency of DIC (1.8 ml, 12 mmol) and about a spatula tip of 4-
(dimethylamino)pyridine for 16 h. The resin was filtered off and washed (DMF 3×, CH2Cl2 3×, 
Et2O 3×) and air-dried. Loading was determined by quantification (UV) of Fmoc cleavage, and 
proved to be 0.77 mmol/g. The resin (130 mg, 100 µmol) was elongated using standard Fmoc-based 
SPPS to give resin-bound N3AcAlaProNle-OH. Where appropriate removal of the Fmoc protecting 
group was accomplished by treatment of the resin-bound peptide with piperidine/DMF (1/4 v/v) for 
20 min. Peptide coupling steps were performed by treatment of the resin with a premixed (5 min) 
solution of the appropriate acid (5 eq.), HCTU (5 eq.) and DiPEA (6 eq.) in NMP (5 ml) for 1 h 
unless stated otherwise. Coupling efficiencies were monitored with the Kaiser test and couplings 
were repeated if necessary. After coupling and deprotection steps the resin was washed with DMF 
(5×). After the last coupling step, the resin was washed extensively (alternating CH2Cl2-MeOH 3×, 
alternating CH2Cl2-Et2O 3×). The resin was treated with TFA/H2O (2 ml, 95/5 v/v) for 2 h, the resin 
was filtered into toluene, the mixture was filtered and the resin washed with TFA (2× 1 ml). The 
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filtrate was diluted (toluene, 10 ml) and concentrated in vacuo. The crude product was coevaporated 
(toluene, 3×). 
AcAlaProNleLeuVSOH (4): Crude AcAlaProNle-OH (100 µmol, prepared via in the same method 
as has been described above for N3AcAlaProNle-OH) was coupled with the TFA-salt of phenolic 
leucine vinyl sulfone and purified as described for N3AcAlaProNleLeuVSOH to give 13.6 mg (23 
µmol, 45%) of the title compound. 1H NMR (DMSO, 300 K, DMX 600): δ, 10.58 (s, 1H), 8.39 (d, 
1H, J = 7.4 Hz), 8.36 (d, 1H, J = 7.3 Hz), 7.92 (d, 1H, J = 5.2 Hz), 7.83-7.80 (m, 2H), 7.60 (d, 2H, J 
= 8.7 Hz), 6.92 (d, 2H, J = 8.7 Hz), 6.73-6.48 (m, 2H), 4.59-4.47 (m, 2H), 4.29-4.26 (m, 1H), 4.07-
4.02 (m, 1H), 2.03-1.95 (m, 1H), 1.90-1.33 (m, 9H), 1.23-1.10 (m, 14H), 0.85-0.79 (m, 7H). 
HRMS: C29H44N4O7S + H+ requires 593.3004, found 593.2995. 
N3AcAlaProNleLeuVSOH (5): Crude N3AcAlaProNle-OH (100 µmol), HATU (38 mg, 0.1 mmol) 
and DiPEA (0.2 ml, 0.12 mmol) were stirred for 5 min in DMF. The TFA-salt of phenolic leucine 
vinyl sulfone (46 mg, 0.12 mmol) and DiPEA (0.3 ml, 0.18 mmol) were added and the mixture was 
stirred for 16 h. The reaction mixture was concentrated in vacuo, the residue was dissolved in 
EtOAc and was washed with 1N HCl, sat. aq. NaHCO3 and sat. aq. NaCl. The organic layer was 
dried with MgSO4 and concentrated in vacuo. The product was purified to homogeneity by RP-
HPLC (linear gradient of 40-50% B in 3 column volumes) to yield 7.43 mg (12 µmol, 12%) of the 
title compound. 1H NMR (DMSO, 300 K, DMX 600): δ, 10.58 (s, 1H), 8.13 (d, 1H, J = 7.5 Hz), 
7.79 (d, 1H, J = 7.6 Hz), 7.77 (d, 1H, J = 8.7 Hz), 7.60 (d, 2H, J = 8.7 Hz), 6.92 (d, 2H, J = 8.7 Hz), 
6.69 (dd, 1H, J = 15.0 Hz, J = 4.9 Hz), 6.55 (dd, 1H, J = 15.0 Hz, J = 1.3 Hz), 4.56-4.48 (m, 1H), 
4.27-4.22 (m, 1H), 4.07-4.02 (m, 1H), 3.61-3.50 (m, 2H), 2.04-1.94 (m, 1H), 1.88-1.72 (m, 4H), 
1.63-1.30 (m, 5H), 1.24-1.09 (m, 14H), 0.86-0.77 (m, 7H). HRMS: C29H43N7O7S + H+ requires 
633.2928, found 633.2935. 
Tert-butyl (4,7,10-trioxa-13-(biotinylamino)tridecyl) carbamate (10): Biotin (488 mg, 2.2 mmol) 
and HCTU (826 mg, 2 mmol) were dissolved in DMF (5 ml) and DiPEA (0.40 ml, 2.4 mmol) was 
added, upon which the reaction mixture turned brown. (1-(tert-butyloxycarbonyl-amino)-4,7,10-
trioxa-13-tridecanamine) 9 (704 mg, 2.2 mmol) was added slowly and the reaction mixture was 
stirred and turned red. After 2 h, TLC-analysis (CHCl3/CH3OH 5/1 v/v) indicated a completed 
reaction. The mixture was concentrated in vacuo, the residue was taken up in CH2Cl2 and washed 
(1N HCl 2×, saturated NaHCO3), dried (MgSO4) and filtered. The filtrate was concentrated in vacuo 
to yield 1.3 g of a brown oil, which was used without further purification. 
4,7,10-Trioxa-13-(biotinylamino)tridecylammonium trifluoroacetate (11): Crude 10 (1.3 g, 2.0 
mmol) was stirred in TFA (2 ml) with water (1 drop). After 1 h, TLC-analysis (CHCl3/CH3OH 5/1 
v/v) indicated a completed reaction. The mixture was concentrated in vacuo, and coevaporated (3× 
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toluene and 3× methanol). The residue was taken up in 3 ml methanol and poured into Et2O (200 
ml). Slowly, a syrup formed on the surface of the flask. The mother liquor was decanted and the oil 
(750 mg, 56% over two steps) was collected. 
Methyl-2-(diphenylphosphino)-4-(4,7,10-trioxa-13-(biotinylamino)tridecylamino)-
carbonyl)benzoic acid (12): Crude 11 (375 mg, 0.56 mmol) was treated with a preactivated 
solution of 2-(diphenylphosphino)-4-(methoxycarbonyl)benzoic acid (236 mg, 0.65 mmol), HOBt 
(88 mg, 0.65 mmol), EDC (128 mg, 0.67 mmol) in CH2Cl2 under argon atmosphere in the presence 
of DiPEA (0.1 ml, 0.67 mmol). The mixture was stirred for 16 hour under argon atmosphere and 
LC/MS analysis indicated a completed reaction. The reaction mixture was diluted (CH2Cl2) and 
washed (1N HCl 2×, saturated NaHCO3 2×), dried (MgSO4) and filtered. The filtrate was 
concentrated in vacuo and the residue was purified (SiO2; CH2Cl2/CH3OH 16/1 v/v) to yield a 
yellow syrup (112 mg, 0.14 mmol, 22%). The product was taken up in CH3CN/CH3OH (1/1 v/v) 
and lyophilised into 5.4 mg aliquots that were stored at -20°C under argon atmosphere. LC/MS-
analysis (10-90% B, rt=13.79 min) indicated that the purity of the product was 88%. [M+H]+ = 
793.5, [M+2H]2+ = 397.3. 1H NMR (200 MHz, CD3OD): δ 7.95 (dd, J=3.3, 8.0, 1H), 7.67 (dd, 
J=1.7, 8.2, 1H), 7.32 (dd, 1.5, 4.0, 1H), 7.3-7.1 (m, 10H), 4.36 (dd, J=4.0, 8.0, 1H), 4.16 (dd, 4.4, 
7.7, 1H), 3.58 (s, 3H), 3.5-3.0 (m, 18H), 2.80 (dd, J=4.7, 12.8, 1H), 2.58 (d, 12.8 Hz, 1H), 2.07 (t, 
J=7.1, 2H), 1.7-1.3 (m, 10H). 13C NMR (50.1 MHz, CD3OD): δ, 175.8, 169.0, 168.1, 165.9, 142.6, 
142.0, 139.0, 138.6, 138.4, 137.8, 135.2, 134.8, 134.4, 131.6, 130.1, 129.8, 129.6, 127.7, 71.4, 71.2, 
69.9, 69.8, 63.2, 61.5, 56.9, 52.7, 41.1, 38.7, 36.8, 30.4, 30.2, 29.7, 29.4, 26.8. 31P NMR (50.1 MHz, 
CD3OD): δ, -2.72. HRMS: C41H53N4O8PS + H+ requires 793.3395, found 793.3384. 
Continuous assay of peptidase activities on a fluorescent plate reader: An assay of proteasome 
activity was performed on a 96-well plate. The ssay mixture was prepared by mixing 100 µl of 2× 
substrate, 50 µl of buffer (or 4× inhibitor), and 50 µl of 4× enzyme (or extract) to give a final assay 
volume of 200 µl. Substrates used were Suc-LLVY-amc for chymotrypsin-like sites, Ac-nLPnLD-
amc for caspase-like sites and Ac-RLR-amc for trypsin-like sites, all at a final concentration of 100 
µM. All substrates were initially prepared as 100× stocks in DMSO. All peptidase assays of the 26S 
proteasome use the same assay buffer, which consists of 50 mM Tris-HCl, pH 7.5, 40 mM KCl, 5 
mM MgCl2, 0.5 mM ATP and 1 mM dithiothreitol (DTT). ATP is needed to prevent dissociation of 
the 26S proteasome into its components, to ensure maximal activity, and in a way that 26S and not 
20S activity is measured. The plate was then placed in a fluorescent plate reader, and the 
fluorescence of 4-amino-7-methyl-coumarin reaction product was monitored continuously 
(excitation 380 nm and emission 460 nm were used). The reaction rates were determined from the 
slopes of the reaction progress curves. In order to account for the contribution of other proteases 
that may be present in extracts to the cleavage of proteasomal substrates, extracts were preincubated 
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in the presence or absence of 20 µM epoxomicin for 30 min at 37°C. For each sample, the 
proteasome activity was calculated by subtracting activity in the epoxomicin-treated extract from 
the activity in the mock-treated extracts.14 
Determination of inhibition of proteasomes in cells: To determine the effect of the inhibitors in 
living cells, cells were incubated at 37°C overnight with varying concentrations of inhibitor. Cells 
were then washed three times in ice cold 1× PBS by centrifugation at 4°C. The cells were frozen 
briefly at -80°C. After thawing, the cells were re-suspended in 4 volumes of homogenization buffer 
(50 mM Tris-HCl, pH 7.5, 250 mM sucrose, 5 mM MgCl2, 2 mM ATP, 1 mM DTT, 0.5 mM EDTA) 
containing 0.025% digitonin. Cells were then incubated for at least 5 minutes on ice to allow 
permeabilization by digitonin. The cytosol was then “squeezed out” by centrifugation at 20.000×g 
for 15 min (4°C). Protein concentration of the extract was determined by Bradford assay. The 
extract was then assayed as above or treated with 0.5 mM phosphane, and analyzed on a SDS-PAGE 
(12% Novex NuPAGE Bis-Tris gel with MOPS running buffer) or 2D-gels (using Invitrogen 
ZOOM system with pH 3-10 isoelectric focusing strips, and a 4-12% gradient NuPAGE Bis-Tris gel 
with MOPS buffer). In some cases, the remaining cell pellet was re-suspended in the same 
homogenization buffer and then sonicated to extract the remaining components. The extracts were 
then analyzed by SDS-PAGE exactly as described for cytosolic extracts. 
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Development of an isotope-coded activity 
based probe for the quantitative profiling 




Proteomics research aims at the study of the expression levels and functioning of 
(subsets of) the proteins present in a biological sample. Proteomics research presents a 
number of challenges to the researchers. The protein content in a cell is dynamic and cannot 
be amplified easily. Further, there is a difference of several orders of magnitude between 
the most and the least abundant proteins. Traditionally, 2D-gel electrophoresis has been 
used to separate mixtures of proteins, allowing identification of the proteins, originally 
using Edman degradation. Nowadays, protein sequencing is normally performed using 
mass spectrometry techniques, as introduced by Watanabe and coworkers in their 
groundbreaking report.2 This mass spectrometry based approach also opened the way to 
quantitative analyses on protein fragments. 
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The use of isotope labeled amino acids for relative quantification of protein was 
introduced by the group of Chait.3 Isotopic labeling was accomplished by growing cells on 
15N enriched growth media. Two cell pools, one isotope labeled and one unlabeled, are 
mixed, lysed and digested with trypsin. The two isotope forms of each peptide have very 
similar chromatographic properties. In practical applications, they coelute and therefore can 
serve as mutual internal standards in the mass spectrometer. The relative intensity of both 
peptides reflects the relative abundance of the protein in the two cell pools. The amino acid 
sequence of the peptides, and thereby the identity of the proteins they originated from, was 
established by tandem ms. 
Aebersold and coworkers used an isotope coded affinity tag (ICAT) to introduce an 
affinity tag, biotin, and an isotope label.4 The ICAT strategy is based on the presence of 
eight D (heavy) or H (light) atoms in a biotin-containing cysteine-reactive probe. The light 
and heavy probe share almost all physical and chemical properties, and only in a mass 
spectrometer the mass difference is revealed. After labeling a denatured protein sample 
from two different sources with either the light or heavy ICAT probe, the combined 
fragments are digested using trypsin. The biotinylated fragments are enriched for, and both 
the relative quantity and sequence identity of the proteins from which the biotinylated 
peptides originated are determined by automated multistage mass spectrometry.5 By 
selecting only cysteine containing tryptic peptides the sample complexity is reduced while 
protein quantification and identification are still achieved. ICAT experiments have been 
used by others to study the influence of perturbations on protein expression levels, to gain 
new insights in specific cellular processes, and to study protein complexes and post-
translational modifications.6 
Quantitative activity based profiling 
In chemical proteomics approaches, a complex biological mixture of proteins is 
simplified before analysis by labeling a specific set of related proteins with an affinity- or 
fluorescence tag.7 For instance, broad-spectrum, irreversible protease inhibitors have been 
used in the profiling of serine proteases,8 cysteine proteases,9 and the catalytically active 
subunits of the proteasome.10, 11 A relevant example of a chemical proteomics probe is 
represented by 1a (DCG-04, Figure 1), developed by Bogyo and coworkers as an 
irreversible cysteine protease inhibitor, and applied by Lennon-Duménil et al. to monitor 
the proteolytic activity of maturing phagosomes in live antigen-presenting cells.12,13 
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Compound 1a consists of 
three functionalities: 1) an 
electrophilic epoxysuccinate, 
that alkylates the active site 
cysteine residue, 2) a short 
peptide sequence that allows 
recognition of the probe by 
the cathepsin family of 
cysteine proteases and 3) 
biotin, for the detection and 
isolation of the modified 
enzymes (Figure 1). The 
biotin is connected to the 
peptide epoxysuccinate by an 
aminohexanoic acid residue. It 
was reasoned that 
incorporation of an isotopic encoded entity, in analogy to the ICAT reagent,4 would allow 
for both quantitative and functional assessment of the cathepsin family of cysteine 
proteases from complex biological samples. 
Synthesis 
Here, the syntheses of a new azide-protected amino acid spacer, 7-azido-3-
oxaheptanoic acid (N3-Aoh-OH, 14a) and two d8-enriched amino acids, 2,2,3,3,4,4,5,5 
octadeutero-6-(Fmoc-amino)hexanoic acid (Fmoc-Ahx-OH-D8, 7) and 4,4,5,5,6,6,7,7-
octadeutero-7-azido-3-oxaheptanoic acid (N3-Aoh-OH-D8, 14b) are described. Their use in 
the synthesis of two sets of DCG-04-based isotopic encoded activity based probes, namely 
compound 1b (in combination with DCG-04 1a) and compounds 2a and 2b is 
demonstrated. It is also shown here that neither incorporation of an isotopic label 
(compounds 1b and 2b, Figure 1) nor substitution of the aminohexanoic acid moiety by an 
7-amino-3-oxa-heptanoic acid residue (compounds 2ab) affects the broad spectrum affinity 























































1a      = CH2
1b      = CD2
2a      = CH2
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6 R = Bn,       = CD2
7 R = H,         = CD2
c543
Scheme 1. Synthesis of deuterated Fmoc-Ahx-OH 7. Reagents and conditions: a) CuCl, N,N,N',N'-
tetramethylene ethylenediamine (TMEDA), O2, THF, 45°C, 36% yield; b) D2, EtOAc, Pd/C, 84% 
yield; c) DCl in D2O, dioxane, 4 h, 90°C, 85% yield. 
The synthesis of Fmoc-Ahx-OH-D8 (7; Scheme 1) starts with a copper(I) catalyzed 
oxidative Glaser coupling14 of Fmoc-protected propargylamine15 (3) and benzyl 
propiolate16 (4) to furnish diyne 5. Upon reduction of diyne 5 with deuterium gas and 
palladium on carbon, the benzyl ester remained intact, yielding deuterated 6. Contrary to 
the results of reduction of several analogs of 5,17 no isotopic scrambling had taken place as 
judged from the isotope distribution in the products. Finally, the benzyl ester was 
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12b R = H,       = CD2
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9 R = H,         = CD2
10 R = Ts,        = CD2
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13b R = tBu,      = CD2
14b R = H,       = CD2  
Scheme 2. Synthesis of azidooxaheptanioc acids 14a and 14b. Reagents and conditions: a) TrCl, 
Et3N, DMAP, 23% yield, 68% recovered 8; b) TsCl, Et3N, 95% yield; c) NaN3, DMF, 50°C, 
quantitative; d) TFA, TES, CH2Cl2, 83% yield; e) tert-butyl bromoacetate, Bu4NBr, NaOH, H2O, 
toluene, 61% (13a and 13b) yield; f) TFA/CH2Cl2 (1/1 v/v), 81% (14a) and 87% (14b) yield. 
The syntheses of N3-Aoh-OH-D0 (14a) and N3-Aoh-OH-D8 (14b) were 
accomplished as follows (Scheme 2). Upon tritylation of deuterated 8, monotrityl ether 9 
was obtained in 23% yield, while the unreacted deuterated butanediol was recovered easily 
(68%). Tosylation of the primary alcohol followed by the replacement of the tosylate by 
azide gave protected azidoalcohol 11. Detritylation (TFA/TES in CH2Cl2) afforded 
azidoalcohol 12b. Both known 4-azido-1-butanol19 12a and deuterated 12b were alkylated 
under phase transfer conditions with tert-butyl bromoacetate to furnish the corresponding 
tert-butyl ester 13a and 13b. Subsequent acidolysis of the tert-butyl esters employing 
TFA/CH2Cl2 (1/1 v/v) yielded azido acid 14a in 49% over two steps and 14b in an overall 
yield of 42% over the last five steps. 
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Scheme 3. Synthesis of activity based probes 1ab and 2ab. Reagents and conditions: a) 20% 
piperidine in NMP; b) Fmoc-Lys(Mtt)-OH, HCTU, DiPEA, NMP; c) 1% TFA in CH2Cl2, then biotin, 
HCTU, DiPEA, NMP; d) Fmoc-Ahx-OH or 7, HCTU, DiPEA, NMP; e) 14a or 14b, HCTU, DiPEA, 
NMP; f) Me3P, 20% H2O in dioxane; g) Repeated cycles of SPPS: Fmoc cleavage: 20% piperidine 
in NMP; amino acid condensation: Fmoc- protected amino acid, HCTU, DiPEA, NMP; Fmoc-
protected building blocks were used in the following order: Fmoc-Tyr(tBu)-OH, Fmoc-Leu-OH, 21; 
h) 5% H2O in TFA. 
The incorporation of spacers 7 and 14ab into the respective cysteine protease 
inhibitors 1b and 2ab is shown in Scheme 3. Immobilization of biocytin on a Rink linker 
was accomplished as described in chapter 3. Standard solid phase peptide synthesis (SPPS) 
with the sequential addition of a spacer (7, 14a and 14b, respectively), Fmoc-Tyr(tBu)-OH, 
Fmoc-Leu-OH and ethyl (2S,3S)oxirane-2,3-dicarboxylate 21,20 acidic cleavage from the 
resin and purification by repeated precipitation afforded target compounds 1b, and 2a and 
2b in 34%, 29% and 40%, respectively in 80-90% purity as judged by LC/MS. A small 
portion of each product was purified to homogeneity by RP-HPLC. 
Inhibitory results 
To establish the inhibition profile of the newly synthesized probes, a set of labeling 
experiments with cell lysates of the mouse macrophage cell line J774 was performed. Cell 
lysates were incubated with DCG-04 (1a) as a control and with the new probes 1b, 2a and 
2b for 60 minutes at 37oC. The resulting mixtures were separated by SDS-PAGE. The 
separated proteins were transferred onto a polyvinylidene difluoride (PVDF) membrane, 
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followed by chemiluminescence 
induced by horseradish peroxidase–
streptavidin conjugate (Figure 2). 
Probes 2ab label the cysteine 
proteases Cat B, L, S, and Z in a cell 
lysate with the same efficiency as 
DCG-04, which has been shown 
previously to effectively target these 
proteolytic enzymes.12 This suggests 
that both sets of isotopic coded 
activity based probes 1ab and 2ab are 
viable quantitative functional 
proteomics tools for the cathepsin 
family of cysteine proteases. 
Attempts to synthesize labeled 
Cat B active-site fragment 
Next an experiment was set up to identify the labeled active site of a cysteine 
protease. Recombinant Cat B was labeled with epoxide 1a and treated with trypsin. The 
labeled catalytic cysteine residue, Cys105, is expected to be in the 
DQGSCGSC105WAGGAVEAISDR sequence, originating from proteolytic cleavage after 
Arg100 and Arg120. The tryptic digest was analyzed by mass spectrometry, but the labeled 
active-site fragment could not be found. In order to gain as much information on the 
expected labeled tryptic fragment, it was decided to embark on the synthesis of this 
fragment 22 (Scheme 4). 
The key step in the synthesis of 22 would be the alkylation of Cys105 with epoxide 
1a. To investigate the feasibility of such an alkylation, a series of base catalyzed alkylations 
was performed on pentapeptide 23. The use of solvents such as ethanol, DMF, THF and 
mixtures thereof with DMSO, as well as the use of inorganic bases such as KOH or Na2CO3 
effected hydrolysis of the ethyl ester present in 1a. The reaction proved to proceed with the 
best result using DMSO as solvent and DiPEA as base to afford 24 in moderate efficiency 
as judged by LC/MS analysis. As only a small amount of 22 was needed for mass 







Figure 2. Derivatization of the DCG-04 molecule 
does not alter targeting of active protease species 
in J774 cells. Crude extracts prepared from J774 
cells were labeled for one hour at 37oC with 
different concentrations of compounds 1b, 2a and 
2b. As a control, extracts were pre-heated for 5 
minutes at 100°C prior to labeling (lanes 1, 5 and 
9). Proteins were then separated by SDS-PAGE on 
12.5% gels and labeled polypeptides visualized by 
streptavidin blotting. Polypeptide species 
corresponding to Cat Z, B, S and L are indicated 
based on previous studies.10 
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which Cys102 was protected as an tert butyl disulfide, with probe 1a. However, no product 
formation could be detected by LC/MS analysis. Subjecting the resin-bound and protected 
peptide 26, with only Cys105 liberated, to the same conditions did not afford target 
compound 22 either. 
As alkylation of Cys105 within the context of the tryptic fragment proved to be 
unsuccessful, an attempt was made to incorporate S-alkylated cysteine into the growing 
peptide chain on the solid support. Reaction of protected cysteine 27 with epoxide 1a 
afforded 28. Removal of the acid labile protecting groups and installation of an Fmoc 
protecting group yielded 29, which was purified by recrystallization. This building block 
proved unsuitable for coupling to the growing tryptic digest peptide chain. Where coupling 
of a trityl protected cysteine building block to the N-terminal Trp on the resin was difficult 
and needed double 
couplings, 29 could not 
be coupled to the Trp 
residue at all. 
A third route that 
might lead to 22 was 
found in a double block 
coupling strategy. As 
alkylation of 22 went in 
moderate yield, it was 
expected that reaction of 
30 with 1a would afford 
some 33, which, after 
HPLC purification, 
could be reacted with the 
succinimidyl ester of 
protected N-terminal 
fragment 31. Activation 
of 31 via the same 

















































25: R = H
















Scheme 4. Synthetic routes toward alkylated tryptic digest 
fragment of Cat B. Reagents and conditions: a) 1a, DMSO, 
DiPEA; b) TFA/H2O (95/5 v/v), then Fmoc-OSu, DiPEA, DMSO; 
c) Fmoc based SPPS; d) 31, HOSu, DIC, DMF, then 33. 
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fragment 32 would eventually lead to target 22. However, alkylation of 30 gave product 33 
in a marginal 2% yield after HPLC purification. Transformation of 31 to the corresponding 
succinimidyl ester went uneventful, but subsequent reaction with 33 did not yield any 
product. 
Conclusions 
In summary, the efficient synthesis of two pairs of isotopic coded spacers is 
presented and it is shown that their incorporation into a known cysteine protease inhibitor 
does not alter the inhibitory profile of the label. This opens the way to quantitative 
functional proteomics studies on a functional subset of the proteome, namely the cathepsin 
family of cysteine proteases. One hurdle that remains to be taken is the identification of the 
labeled tryptic digest fragment of the Cat B active site in a mass spectrometric experiment. 
Synthesis of this fragment has not been succesfull, but the shorter peptide fragment that was 
S-alkylated with the cysteine protease probe could be of use as well. Importantly, this 
concept may be extended towards other isotopic coded spacers (13C, 15N) and activity based 
probes targeting other proteins.7 
Experimental section 
General methods and materials: All solvents used in synthesis were of p.a. grade and stored over 
molecular sieves. Pyridine, CH2Cl2, toluene, triethylamine, DiPEA, DMF, NMP, DMSO and TFA 
were bought at Biosolve. Tritylchloride, tosylchloride, 4-(dimethylamino)pyridine, deuterium 
chloride (20 wt% solution in D2O) and triethylsilane were purchased from Acros. 1,1,2,2,3,3,4,4-
Octadeutero-1,4-butanediol, deuterium (99.8% D) and tert-butyl bromoacetate were purchased from 
Aldrich. Sodium azide was bought at Merck. Fmoc-Leu-OH, Fmoc-Tyr(tBu)-OH and Fmoc-
Lys(Mtt)-OH were bought at Senn Chemicals. 
TLC analysis was performed on Merck 25DC Plastikfolien Kieselgel 60 F254, with detection by UV 
absorption (254 nm) and spraying with one of the following solutions: a 20% H2SO4 in EtOH 
followed by charring, b ammonium molybdate (25 g/l) in 10% H2SO4 followed by charring, c 
KMnO4 (10 g/l in 2% aq. Na2CO3). Fluka silica gel (230-400 mesh) was used for column 
chromatography. 1H-NMR and 13C-NMR spectra were recorded with a Bruker AC200 instrument at 
200 and 50.1 MHz, respectively. Chemical shifts (δ) are given in ppm, relative to tetramethylsilane 
as an internal standard. Mass spectra were recorded with a Perkin Elmer Sciex API 165 mass 
instrument equipped with a custom-made Electrospray Interface (ESI). LC/MS analysis was 
performed on a Jasco HPLC system (detection simultaneously at 214 and 254 nm) coupled to a 
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Perkin Elmer Sciex API 165 mass spectrometer equipped with a custom-made Electrospray 
Interface (ESI). An analytical Alltima C18 column (Alltech, 4.6 × 250 mm, 5 µm particle size) was 
used. Buffers: A: H2O; B: CH3CN; C: 0.5% aq TFA. For RP HPLC-purifications a Biocad “Vision” 
automated HPLC system (PerSeptive Biosystems, inc.) was used. The applied buffers were A, B 
and C. High resolution mass spectra were recorded on a Finnigan LTQ-FT (Thermo electron). 
(N-Fluorenylmethyloxycarbonyl)-propargylamine (3): The title compound was prepared 
according to the literature procedure.15 1H and 13C NMR analyses were in agreement with the 
reported values. 
Benzyl propiolate (4): The title compound was prepared according to the literature procedure.16 1H 
and 13C NMR analyses were in agreement with the reported values. 
6-(Fluorenylmethyloxycarbonylamino)-hexa-2,4-diynoic acid benzyl ester (5): In a 100 ml three 
necked reaction flask were placed, Cu(I)Cl (180 mg, 1.79 mmol), TMEDA (0.260 ml, 1.79 mmol), 
THF (20 ml) and N-Fmoc propargyl amine (1.03 g, 3.72 mmol). Oxygen was bubbled through the 
suspension and at 30°C a solution of benzyl propiolate (2.58 g, 16.1 mmol) in THF (20 ml) was 
added dropwise over a 1.5 h period. The reaction was stirred for another 2 h at 40°C while bubbling 
oxygen. The resulting black mixture was diluted with EtOAc (100 ml) and washed subsequently 
with 0.1 M HCl (60 ml) and brine (60 ml). After drying (MgSO4), evaporation of the solvent and 
column chromatography of the black residue (hexanes:EtOAc 95:5 → 9:1 → 3:1), the title 
compound was isolated as an orange/red solid (590 mg, 36 %). 0.60 g N-Fmoc-propargyl amine was 
recovered. 1H-NMR (CDCl3); δ 4.12 (d, 2H, J=5.1 Hz, CH2N); 4.21 (t, 1H, J=6.6 Hz, CH); 4.45 (d, 
2H, J=6.6 Hz, CH2O); 4.98 (broad s, 1H, NH); 5.22 (s, 2H, CH2O); 7.25-7.44 (m, 9H, arom); 7.56 
(d, 2H, J=7.3 Hz, arom); 7.76 (d, 2H, J=7.3 Hz, arom). 13C-NMR (CDCl3); δ 31.2, 46.8, 65.8, 66.9, 
67.3, 67.9, 68.1, 70.7, 119.8, 124.8, 126.9, 127.6, 128.3, 128.5, 134.2, 141.0, 143.4, 152.2, 155.7. 
6-(Fluorenylmethyloxycarbonylamino)–2,2,3,3,4,4,5,5-octadeuterohexanoic acid benzyl ester 
(6): Benzyl ester 5 (307 mg, 0.705 mmol) was dissolved in a mixture of dry 1,4-dioxane (50 ml) 
and D2O (2 ml). The solvents were evaporated in vacuo and the procedure was repeated once. Then 
the residue was dissolved in EtOAc (12 ml) and Pd/C-10% (14 mg) was added. The mixture was 
put in a Parr apparatus and shaken under D2 (2.5 bar) for 4 h. The solution was filtered, 
concentrated and purified by column chromatography (hexanes:EtOAc 9:1 → 3:1), to afford the 
title compound as a pale yellow solid (267 mg, 84 %). 1H-NMR (CDCl3); δ 3.15 (d, 2H, J=5.8 Hz, 
CH2N); 4.21 (t, 1H, J=6.6 Hz, CH); 4.40 (d, 2H, J=6.6 Hz, CH2O); 4.74 (m, 1H, NH); 5.11 (s, 2H, 
CH2O); 7.25-7.39 (m, 9H, arom); 7.58 (d, 2H, J=7.3 Hz, arom); 7.76 (d, 2H, J=7.3 Hz, arom). 13C-
NMR (CDCl3); δ 20.1-21.7 (m), 22.0-23.1 (m), 25.3-26.4 (m), 30.0-31.4 (m), 38.1, 44.8, 63.6, 63.9, 
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117.4, 122.5, 124.5, 125.1, 125.7, 126.0, 133.5, 138.8, 141.5, 154.0, 170.9. ESI-MS m/z 452.1 
[M+H]+, 474.2 [M+Na]+, 903.5 [2M+H]+, 925.6 [2M+Na]+. 
6-(Fluorenylmethyloxycarbonylamino)–2,2,3,3,4,4,5,5-octadeuterohexanoic acid (7): Under 
argon benzyl ester 6 (205 mg, 0.455 mmol) was dissolved in dry 1,4-dioxane (8 ml) and DCl/D2O 
(0.30 ml, 1/4 w/w)) was added. The reaction mixture was stirred at 90°C and after 4 hours TLC 
showed complete conversion of the benzyl ester. The mixture was cooled and the solvents were 
evaporated in vacuo. Purification by column chromatography (hexanes:EtOAc 9:1 → 3:1 → 1:1 
+0.2% HOAc), afforded the target compound as a white solid (140 mg, 85 %). 1H-NMR (CD3OD); 
δ 2.99 (s, 2H, CH2N); 4.10 (t, 1H, J=6.7 Hz, CH); 4.26 (d, 2H, J=6.7 Hz, CH2O); 7.17-7.33 (m, 4H, 
arom); 7.55 (d, 2H, J=7.3 Hz, arom); 7.70 (d, 2H, J=7.3 Hz, arom). 13C-NMR (CD3OD); δ 23.7-
24.9 (m), 25.3-26.7 (m), 28.7-30.1 (m), 33.2-34.7 (m), 41.3, 48.3, 67.4, 120.8, 126.0, 128.0, 128.6, 
142.4, 145.2, 158.7, 177.6. ESI-MS m/z 362.2 [M+H]+, 723.6 [2M+H]+. HRMS [M+H]+ calculated: 
362.220, found: 362.220. 
1,1,2,2,3,3,4,4-Octadeutero-4-trityloxybutan-1-ol (9): A mixture of 1,1,2,2,3,3,4,4-octadeutero-
1,4-butanediol (2.0 g, 20.4 mmol), trityl chloride (1.9 g, 6.8 mmol), triethylamine (0.95 ml, 6.8 
mmol) and about a spatula tip of 4-(dimethylamino)pyridine was stirred until TLC-analysis 
indicated consumption of tritylchloride. EtOAc (10 ml) was added and the mixture was filtered and 
concentrated in vacuo. Purification over silica gel (hexanes:EtOAc 6:1→1:1, then EtOAc:MeOH 
9:1) yielded 1.57 g (4.6 mmol, 68% yield to TrCl, 23% conversion of diol) of the title compound. 
1H NMR (CDCl3): δ, 7.35-7.15 (m, 15H, Harom), 1.8 (br. s. 1H OH); 13C NMR (CDCl3): δ, 143.9 
(Cq,arom) 128.1, 127.2, 126.3 (Carom), 86.0 (Cq Tr), 63-59 (m CD2O 2x) 29-27 (m, CD2), 26-24 (m, 
CD2). HRMS [M+Na]+ calculated: 363.217, found: 363.218. 1.36 g (13.8 mmol, 68%) of the 
deuterated diol was recovered. Overall, 91% of the deuterated starting material was converted or 
recovered. 
1,1,2,2,3,3,4,4-Octadeutero-4-trityloxybutanol tosylate (10): To a solution of 9 (1.57 g, 4.6 
mmol) in CH2Cl2 were added triethylamine (1.28 ml, 9.2 mmol, 2 eq.), a catalytic amount of 4-
(dimethylamino)pyridine and tosyl chloride (1.31 g, 6.9 mmol, 1.5 eq.) and the mixture was stirred 
for 3 h, after which TLC-analysis indicated a completed reaction. Excess tosyl chloride was 
quenched by addition of MeOH (5 ml) and the mixture was concentrated in vacuo. The residue was 
taken up in EtOAc, filtered and the filtrate was concentrated in vacuo. The crude product was 
purified over silica gel (hexanes:EtOAc 9:1) to yield 2.16 g (4.4 mmol, 95%) of a white solid. 1H 
NMR (CDCl3): δ, 7.74 (d, 2H, J=9.7 Hz, Harom), 7.4-7.1 (m, 17H, Harom), 2.42 (s, 3H, Me); 13C NMR 
(CDCl3): δ, 144.4, 143.9, 132.9 (Cq,arom), 129.6, 128.3, 127.8, 127.5, 126.7 (Carom), 86.1 (Cq Tr), 21.3 
(Me). HRMS [M+Na]+ calculated: 517.229, found: 517.227. 
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1,1,2,2,3,3,4,4-Octadeutero-4-trityloxybutane azide (11): To a solution of 10 (2.2 g, 4.4 mmol) in 
DMF was added sodium azide (426 mg, 6.55 mmol, 1.5 eq.) and the mixture was stirred at 50°C 
until TLC analysis indicated consumption of tosylate 2. The reaction mixture was concentrated in 
vacuo, taken up in Et2O and washed (H2O, 3×). The combined water layers were extracted with 
Et2O. The combined organic layers were dried over MgSO4, filtered and concentrated in vacuo to 
yield 1.68 g (quant.) of a colourless oil. 1H NMR (CDCl3): δ, 7.5-7.1 (m, 15H, Harom); 13C NMR 
(CDCl3): δ, 143.8 (Cq,arom) 128.0, 127.2, 126.4 (Carom), 85.9 (Cq Tr), 62-60 (m, CD2O), 51-49 (m, 
CD2N3), 26-24 (m, CD2 2×). 
1,1,2,2,3,3,4,4-Octadeutero-4-azidobutan-1-ol (12b): To a stirred solution of 11 (1.6 g, 4.37 
mmol) and triethylsilane (1 ml, 6.5 mmol, 1.5 eq.) in CH2Cl2 (2.5 ml) was added TFA dropwise, 
until no more yellow colour of trityl cations was observed, and the mixture was stirred for 15 min. 
The mixture was concentrated in vacuo, and purified over silica gel (hexanes:EtOAc 9:1, 4cv, then 
hexanes:EtOAc 1:1, 4cv) to yield 445 mg (3.6 mmol, 83%) of a yellow oil. 1H NMR (200 MHz, 
CDCl3): δ, 5.11 (br s, 1H, OH); 13C NMR (CDCl3): δ, 61-59 (m, CD2OH), 51-49 (m, CD2N3), 29-27 
(m, CD2), 25-23 (m, CD2). 
7-Azido-3-oxoheptanoic acid tert-butyl ester (13a): To a solution of known21 4-azido-butane-1-ol 
(1.7 g, 15 mmol), tert-butyl bromoacetate (4.2 ml, 30 mmol, 2 eq.), tetrabutylammonium bromide 
(490 mg, 3 mmol, 10 mol%) and a catalytic amount of tetrabutylammonium iodide in toluene (60 
ml) was added aq. NaOH (60 ml, 50% by weight) and the mixture was stirred vigorously at ambient 
temperature until TLC-analysis indicated consumption of 12a. Water (600 ml) was added to the 
mixture, and stirring was continued for 1 h. The organic layer was separated and the aq. layer 
extracted with toluene (3×). The combined organic layers were washed (sat. aq. NH4Cl, sat. aq. 
NaHCO3, brine), dried over MgSO4 and concentrated in vacuo. Purification of the crude product 
over silica gel (hexanes:EtOAc 9:1) yielded 2.1 g (9.1 mmol, 61%) of a yellow liquid. 1H NMR 
(CDCl3): δ, 3.95 (s 2H, CH2C=O), 3.6-3.5 (m, 2H, CH2O), 3.25-3.15 (m, 2H, CH2N3), 1.8-1.65 (m, 
4H, CH2 2x), 1.48 (s, 9H, tBu); 13C NMR (CDCl3): δ, 168.7 (C=O), 80.3 (Cq tBu), 69.8 (CH2O), 
67.8 (CH2C=O), 50.3 (CH2N3), 26.0, 24.9 (m, CH2). HRMS [M+H]+ calculated: 230.150, found: 
230.150. 
4,4,5,5,6,6,7,7-octadeutero-7-azido-3-oxaheptanoic acid tert-butyl ester (13b): To a solution of 
12b (445 mg, 3.6 mmol), tert-butyl bromoacetate (1.06 ml, 7.2 mmol, 2 eq.), tetrabutylammonium 
bromide (119 mg, 0.36 mmol, 10 mol%) and a catalytic amount of tetrabutylammonium iodide in 
toluene (15 ml) was added aq. NaOH (15 ml, 50% by weight) and the mixture was stirred 
vigorously at ambient temperature until TLC-analysis indicated consumption of 12b. Water (150 
ml) was added to the mixture, and stirring was continued for 1 h. The organic layer was separated 
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and the aq. layer extracted with toluene (3×). The combined organic layers were washed (sat. aq. 
NH4Cl, sat. aq. NaHCO3, brine), dried over MgSO4 and concentrated in vacuo. Purification of the 
crude product over silica gel (hexanes:EtOAc 9:1) yielded 530 mg (2.2 mmol, 61%) as a colourless 
oil. 1H NMR (CDCl3): δ, 3.94 (s 2H, CH2), 1.48 (s, 9H, tBu); 13C NMR (CDCl3): δ, 169.1 (C=O), 
80.7 (Cq tBu), 70-68 (m CD2O), 68.0 (CH2), 50-48 (m CD2N3), 26-23 (m, CD2 2×). 
7-azido-3-oxoheptanoic acid (14a): tert-Butyl ester 13a (1 g, 4.3 mmol) was treated with 
TFA/CH2Cl2 (20 ml, 1/1 v/v) for 2 h at ambient temperature. Toluene (20 ml) was added, and the 
mixture was concentrated to half its volume. Toluene (20 ml) was added again and the mixture was 
coevaporated with toluene 3× to remove residual TFA. The resulting yellow oil was dissolved in 
EtOAc and extracted with sat. aq. NaHCO3 (3×). The organic layer was discarded, the aqueous 
layer acidified with conc. HCl to pH 1 and extracted with Et2O (6×). The combined Et2O layers 
were dried (MgSO4), filtered and concentrated in vacuo to yield 610 mg (3.5 mmol, 81%) of a 
yellowish oil. 1H NMR (CDCl3): δ, 10.68 (br s, 1H, COOH), 4.15 (s 2H, CH2C=O), 3.65-3.55 (m, 
2H, CH2O), 3.35-3.25 (m, 2H, CH2N3), 1.8-1.6 (m, 4H, CH2 2x); 13C NMR (CDCl3): δ, 175.1 
(C=O), 70.8 (CH2O), 67.1 (CH2C=O), 50.6 (CH2N3), 26.1, 25.0 (m, CH2). HRMS [M+H]+ 
calculated: 174.087 found: 174.088. 
4,4,5,5,6,6,7,7-octadeutero-7-azido-3-oxaheptanoic acid (14b): tert-Butyl ester 13b (530 mg, 2.2 
mmol) was treated with TFA/CH2Cl2 (10 ml, 1/1 v/v) for 2 h at ambient temperature. Toluene (10 
ml) was added, and the mixture was concentrated to half its volume. Toluene (10 ml) was added 
again and the mixture was coevaporated with toluene 3× to remove residual TFA. The resulting 
yellow oil was dissolved in EtOAc and extracted with sat. aq. NaHCO3 (3×). The organic layer was 
discarded, the aqueous layer acidified with conc. HCl to pH 1 and extracted with Et2O (6×). The 
combined Et2O layers were dried (MgSO4), filtered and concentrated in vacuo to yield 346 mg (1.9 
mmol, 87%) of a yellowish oil. 1H NMR (CDCl3): δ, 9.86 (br s, 1H, COOH), 4.14 (s 2H, CH2); 13C 
NMR (CDCl3): δ, 175.0 (C=O), 71-69 (m CD2O), 66.9 (CH2), 51-49 (m CD2N3), 26-23 (m, CD2 
2×). ESI-MS:[M+Na]=204.0. 
Ethyl (2S,3S)oxirane-2,3-dicarboxylate (21): The title compound was prepared according to the 
literature procedure.20 1H and 13C analysis were in agreement with the reported value. αD22 +105 (c 
1.2, Et2O). As a control, Ethyl (2R, 3R)oxirane-2,3-dicarboxylate was prepared following the same 
procedure. αD22 -114 (c 1.2, Et2O). 
Synthesis of the novel DCG-04 analogues: Fmoc Rink amide resin (78 mg, 50 µmol) was 
elongated by standard Fmoc-based SPPS. Where appropriate removal of the Fmoc protecting group 
was accomplished by treatment of the resin-bound peptide with 20% (v/v) piperidine in NMP for 20 
minutes. Peptide coupling steps were performed by treatment of the resin with a premixed (5 min) 
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solution of the of the appropriate acid (5 eq.), HCTU (5 eq.) and DiPEA (6 eq.) in NMP (0.5 ml) for 
1 h unless stated otherwise. Coupling efficiencies were monitored with the Kaiser test and couplings 
were repeated if necessary. After coupling and deprotecting steps the resin was washed with DMF 
(5×). Lysine side chain Mtt protecting groups were removed by treatment of the resin with 1% TFA 
in CH2Cl2 (4×10 min) The resin was washed (CH2Cl2 5×, then NMP 2×) and neutralized with 10% 
DiPEA in NMP. Azides were reduced to amines on solid phase by treatment of the resin, after 
washing (dioxane 5×), with Me3P (0.3 ml 1M in toluene, 0.3 mmol, 6 eq.) in dioxane/H2O (4/1 v/v, 
1 ml) for 40 min, followed by extensive washing of the resin (dioxane 3×, alternating CH2Cl2-
MeOH 3×, and NMP 3×). Deuterated building blocks 7 and 14b were coupled using 2 eq. of the 
appropriate acid. After coupling of known 21 to the immobilised peptide, the resin was washed 
extensively (alternating CH2Cl2-MeOH 3×, alternating CH2Cl2-Et2O 3×. The resin was transferred 
into a clean vial, washed with CH2Cl2 and treated with TFA/H2O (1 ml, 95/5 v/v) for 2 h. The 
mixture was filtered and the resin washed with TFA (2× 1 ml). The filtrate was diluted (toluene, 10 
ml) and concentrated in vacuo. To the residue, toluene was added and the concentration was 
repeated. The residue was taken up in MeOH pored into Et2O. The precipitate was filtered off and 
washed with Et2O. This precipitation was repeated to give the DCG-04 analogues in 29-40% yield. 
A portion of every analogue was purified to homogeneity by RP-HPLC, applying a linear gradient 
(20-40% B in 3 column volumes). 1b was isolated in 34% yield. HRMS [M+H]+ calculated: 
933.497, found: 933.505. 2a was isolated in 29% yield. HRMS [M+H]+ calculated: 941.441, found: 
941.449. 2b was isolated in 40% yield. HRMS [M+H]+ calculated: 949.492, found: 949.499. 
Peptide 24: Fmoc Rink amide resin (78 mg, 50 µmol) was elongated by manual solid phase peptide 
synthesis to give Ac-SCWAFG-NH2 after cleavage from the resin. 23 was obtained as indicated 
above. 9 mg (2.5 µmol) of the crude product and 1a (6 mg, 6 µmol) were dissolved in DMSO 
saturated with argon and DiPEA (5 µl) was added. The reaction mixture was stirred under argon 
atmosphere, and after 3 h, LC/MS analysis indicated formation of target 24, as well as saponified 
1a, saponified 24 and the disulfide of 24. Longer reaction times resulted in more saponifiaction, 
whereas shorter reaction times resulted in less product formation as well. As judged by LC/MS, the 
yield of the reaction was estimated around 30%. 
Peptide 25: Tentagel HMB resin preloaded with Fmoc-Arg (50 µmol) was elongated using 
automated standard Fmoc-based SPPS, except for the two difficult couplings after the Trp residue, 
where double couplings of 2 h were applied. The peptide was cleaved from the resin with 
TFA/H2O/TIS (95/2.5/2.5 v/v/v), purified by RP-HPLC and reacted with 1a as described for 
compound 24. LC/MS analysis gave no indication for formation of 22. Also, removal of the Mmt 
protecting group of the target cysteine residue on the solid support followed by on-resin alkylation 
with 1a did not result in productive alkylation. 
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Boc-Cys(DCG-04)-OtBu (28): To a solution of Boc-Cys-OtBu (26) (28 mg, 0.1 mmol), 1a (90 mg, 
0.1 mmol) in DMSO (2 ml) saturated with argon, DiPEA (68 µl, 0.4 µmol) was added and the 
mixture was stirred for 3 h. The reaction mixture was poured into Et2O/EtOAc (30 ml, 1/1 v/v), 
cooled (0°C) and agitated to aid precipitation. The white precipitate was collected by centrifugation 
and washed (Et2O) to yield 111 mg (94 µmol, 94%) of a white powder, with a purity of 90% as 
judged from LC/MS. [M+H]+ calculated for C55H89N9O15S2: 1180.5, found: 1180.9. 
Fmoc-Cys(DCG-04)-OH (29): Crude 28 (94 µmol) was treated with TFA/H2O (1 ml, 95/5 v/v) for 
3 h. The product was precipitated with cold Et2O (35), aided by vortexing. The white precipitate 
was collected by centrifugation and washed (Et2O), and redissolved in DMSO (1 ml) with Fmoc-
OSu (95 mg) and DiPEA (124 µl). After 3 h of stirring, the mixture was poured into Et2O (30 ml) 
and left for precipitation for 16 h at 4°C. The precipitate was collected by centrifugation and washed 
(Et2O), to yield 78 mg (47 µmol, 50%) of the target compound. LC/MS [M+H]+ calculated for 
C61H83N9O15S2: 1245.6, found: 1245.5. Attempts to couple this alkylated cysteine to the Trp residue 
of growing peptide chain WAFGAVEAISDR remained fruitless. 
Boc-D(tBu)Q(Tr)GS(tBu)C(Tr)G-OH (31): Peptide 31 was synthesized on hyper acid labile 
Fmoc-Gly-HMPB tentagel resin. The protected peptide was cleaved from the resin by batchwise 
treatment with 1% TFA in CH2Cl2 (20 × 1 ml) for 0.5 min and immediate neutralization of the 
acidic batches in MeOH/pyridine (10 ml, 9/1 v/v). The solution was concentrated in vacuo and 31 
was purified to homogeneity by RP-HPLC on a semi-preperative Alltima CN column (Alltech, 10 × 
250 mm, 5 µm particle size) and the A-buffer replaced by H2O/MeOH (1/1 v/v) to yield 5 mg (4 
µmol, 8%) of the target compound. LC/MS [M+H]+ calculated for C70H83N7O13S: 1262.6, found: 
1262.7. 
H-SC(DCG-04)WAFG-OH (33): Peptide 30 was synthesized on 50 µmol resin using automated 
standard Fmoc-based SPPS and cleavage of the product from resin by treatment with TFA/H2O/TIS 
(95/2.5/2.5 v/v/v). Peptide 30 was precipitated (Et2O) and used without any further purification. 
LC/MS [M+H]+ calculated for C31H39N7O8S: 670.2, found: 670.4. 30 (50 µmol) was dissolved in 
DMSO (1.5 ml) and 1a (54 mg, 60 µmol) was added. The mixture was saturated with argon before 
DiPEA (250 µmol, 40 µl) was added, and the reaction mixture was stirred under an argon 
atmosphere for 16 h. LC/MS analysis of the reaction mixture indicated formation of 33, as well as 
peptide disulfide formation. 33 was purified to homogeneity by RP-HPLC to yield 1.5 mg (1 µmol, 
2%) of the target compound. LC/MS [M+H]+ calculated for C74H105N15O19S2: 1572.7, found: 
1572.9. 
34: Activation of 31 (4 µmol) with DIC (1 µl, 4 µmol) and N-hydroxysuccinimide (1.2 mg, 10 
µmol) in DMF (0.5 ml) was confirmed by LC/MS analysis after 2 h. LC/MS [M+H]+ calculated for 
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C74H86N8O15S: 1359.6, found: 1359.9. The activated ester solution and DiPEA (4 µmol) were added 
to 33 (1 µmol) and the mixture was stirred for 16 h. LC/MS analysis did not reveal the presence for 
target 34. 
Active site labeling of cysteine proteases in J774 cell lysates and detection by streptavidin- 
blotting: The mouse macrophage cell line J774 was cultured in Dulbecco's Modified Eagle's 
medium containing 10% fetal calf serum (FCS), 1% penicillin/streptomycine and 1% glutamine. 
Cells were harvested by centrifugation at 4°C, washed in phosphate buffered saline (PBS) pH 6.8 
and cell pellets corresponding to 5 × 107 cells were frozen at –80°C. Cell pellets were thawed on ice 
and lysed in 100 µl lysis buffer pH 5 (50 mM NaOAc pH 5, 5 mM MgCl2, 0.5% Nonidet-P40), 
incubated for 30 minutes and centrifuged for 15 min at 13.000 × g to remove nuclei. Protein 
concentration of the cell extract was measured using the BioRad Protein Assay with bovine serum 
albumin as standard. Cell lysate (25 µg protein) was incubated with DCG-04, 1b, 2a and 2b 
respectively for 60 min at 37°C. The reaction was stopped by addition of double concentrated, 
reducing Laemmli sample buffer and boiling for 10 min. Samples were analyzed by SDS-PAGE 
and transferred to a polyvinylidene membrane (Immobilon P; Millipore). After blocking over-night 
in phosphate-buffered saline (PBS) pH 7.2 containing 10% non-fat dry milk, the membrane was 
incubated with strept-HRP (1:2500; Amersham) in PBS containing 0.2% Tween 20 for 60 min at 
room temperature followed by extensive washing in PBS-Tween. Polypeptide species reactive to 
the compounds were detected by Enhanced Chemiluminescence (ECL NEN; Perkin Elmer). 
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A cysteine protease probe with an 




Phagocytosis is, in many cases, the first step towards the presentation of exogenic 
antigenic proteins on MHC class II molecules of professional antigen presenting cells.2 The 
ingested antigens travel to the lysosomes and are degraded by a set of different hydrolases. 
Some of the peptide fragments generated by these proteases escape further degradation by 
binding to MHC class II molecules. The loaded MHC class II molecules are transported to 
the cell surface for presentation to CD4+ T-cells (helper T cells). Depending on other 
factors, like the conditions of the antigen presentation, the CD4+ T-cells can initiate a B-
lymphocyte or CD8+ cytotoxic T-lymphocyte mediated immune response. 
The cathepsin family of lysosomal cysteine proteases plays an important role in the 
process of antigen processing: these proteases are able to cleave the majority of peptide 
bonds in antigens.3 The activity of the different proteases in the lysosomal pathway is not 
constant.4 Different protease activities are added to the maturing lysosome sequentially and 
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the activity of all proteases is 
also dependent on the pH. As a 
result, the processing of 
epitopes is governed by 
gradients of tightly regulated 
protease activities. 
Here, a cysteine 
protease probe is described for 
use in the monitoring of the 
activity of the lysosomal 
cysteine proteases that a model 
antigen encounters after 
internalisation. The new probe contains an amine reactive group to allow conjugation to a 
model antigen, as well as a photolabile linker to release the probe from the model antigen 
before analysis of the target proteases. A known cysteine protease activity based probe, 
DCG-04,5 was equipped with an activated ester to facilitate conjugation of this probe to a 
lysine side chain amine of an antigen of choice (1, Figure 1). In a typical experiment, probe 
1 could be conjugated to ovalbumin (2) to furnish construct 3 (Figure 2). This 
ovalbuminated probe captures an active cathepsin of the cysteine protease family to give 4. 
This way, the biotin-bearing cysteine protease probe has become covalently bound to the 
targeted cysteine protease. An photolabile ortho-nitrobenzyl linker would allow for 
photorelease of the ovalbumin carrier protein, and biotinylated cathepsin 5 could be 















Figure 2. Schematic representation of the cathepsin labeling approach. Ovalbumin (OVA) is 
conjugated to probe 1, a cathepsin (Cat) reacts with the probe and OVA is photoreleased to furnish 










































Figure 1. Target structure 
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Synthesis 
The first route of synthesis that was explored is depicted in Scheme 1. Suitable protected 
photocleavable linker 3 (Scheme 1) was obtained by Boc-protection of known photolabile 
amino acid 2.6 Immobilised biocytin was created as described in Chapter 3 and elongated 
with Fmoc-Lys(Mtt)-OH to afford 4. The lysine side chain amine was liberated by 
treatment with 1% TFA in CH2Cl2, followed by acylation with Boc-protected nitrovaleryl 























































































































Scheme 1. Synthesis of photocleavable activated probe 1. Reagents and conditions: a) Boc2O, 
dioxane, H2O, NaOH; b) 20% piperidine in NMP, then Fmoc-Lys(Mtt)-OH, HCTU, DiPEA, NMP; c) 
1% TFA in CH2Cl2, then biotin, HCTU, DiPEA, NMP; d) 1% TFA in CH2Cl2 then 3, HCTU, DiPEA, 
NMP; e) Repeated cycles of SPPS: Fmoc cleavage: 20% piperidine in NMP; amino acid 
condensation: Fmoc-protected amino acid, HCTU, DiPEA, NMP; Fmoc-protected building blocks 
were used in the following order: Fmoc-Ahx-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Leu-OH, 7; f) TFA/H2O 
(95/5 v/v); g) 8, DiPEA, DMF. 
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give protected and immobilized 6. The peptide was cleaved from the resin by treatment 
with TFA/H2O/TIS, removing also the acid labile side chain protecting groups. The crude 
intermediate was purified to homogeneity by RP-HPLC and reacted with excess 
bisactivated ester 8. LC/MS analysis confirmed the formation of product 1 but HPLC 
purifications did not effect separation of the target compound from the excess of 8. 
To circumvent this purification problem, it was decided to perform all coupling 
steps on the solid support. For this purpose, activated ester 9 (Scheme 2) was prepared by 
reaction of photolabile linker 5 with disuccinimidyl suberate 8. Elongation of 4 by standard 
Fmoc-based SPPS afforded Mtt-protected immobilised peptide 10. After Mtt cleavage, the 
lysine side chain was elaborated using acid 9 at low temperature. Nucleophilic attack on the 
less reactive OSu ester was suppressed by the reaction conditions. Liberation of the peptide 
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Scheme 2. Synthesis of photocleavable activated probe 1. Reagents and conditions: a) 8, Et3N, 
DMF; b) Repeated cycles of SPPS: Fmoc cleavage: 20% piperidine in NMP; amino acid 
condensation: Fmoc-protected amino acid, HCTU, DiPEA, NMP; Fmoc-protected building blocks 
were used in the following order: Fmoc-Ahx-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Leu-OH, 7; c) 1% TFA 
in CH2Cl2; d) 9, HATU, DiPEA, NMP, -20°C; e) TIS/H2O/TFA (2.5/2.5/95 v/v/v). 
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Inhibitory results and photocleavage characteristics 
Next, the photocleavage characteristics of the linker were investigated. Model 
compound 12, conveniently synthesised from 3 in three steps (Scheme 3), was chosen for 
initial studies. Photocleavage proceeded smooth, and after 4 h all starting material had been 









































Scheme 3. Initial photocleavage studies. Reagents and conditions: a) 2-phenylethylamine, DIC, 
DMAP, CH2Cl2, then TFA/CH2Cl2 (1/1 v/v) then Boc-Phe-OH, DIC, DMAP, CH2Cl2; b) 12 was 
dissolved in DMSO/MeOH/MeCN (10/45/45 v/v/v) and two drops of ethanolamine were added. The 
reaction mixture was irradiated in a quartz cuvet using a Rayonet reactor equipped with 7 × 3500 Å 
(15 W) lamps. Samples were taken at t=0, 1 h, 2 h, 4 h, 8 h and analyzed by LC/MS. 
With the photocleavage conditions in hand, an ovalbumin-1 conjugate was 
synthesized. Ovalbumin was incubated with 3 equivalent of OSu ester 1 for 2 h at 4°C, and 
unreacted and hydrolyzed 1 were removed by dialysis. The resulting construct was exposed 
to the action of Cat B at 37°C for 30 min. Western blot analysis indicated the presence of 
biotinylated Cat B, but no heavy band for the Cat B-1-Ova was observed. This observation 
forced us to exclude the presence of 1 after dialysis. 
As a model for the dialysis of 1, ovalbumin was incubated with DCG-04 (compound 
1a, Chapter 4) under the same conditions as 1. Unexpectedly, not only cathepsin labeling 
was found upon incubation with Cat B, but also labeling of ovalbumin was detected by 
Western blotting with strept-HRP. This would indicate that ovalbumin could react with the 
epoxide moiety in DCG-04. To test which nucleophile was responsible for this labeling, 
ovalbumin was treated with maleimide to block all cysteine residues. DCG-04 was added 
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and western blotting indicated no alkylation with DCG-04. However, labeling returned if a 
dialysis step was included after maleimide treatment, albeit with lower efficiency as seen 
before. As a third control, DCG-04 and ovalbumin were mixed in blotting buffer, boiled 
briefly to denaturate and separated on SDS-PAGE. Again, biotinylation was confirmed with 
western blotting. From these experiments, it was concluded that 1) the dialysis protocol is 
insufficient for removal of DCG-04 and possibly also for 1 and 2) that boiling in Laemmli 
sample buffer is sufficient to effect alkylation of cysteine residues within ovalbumin. These 
results demand a proper purification protocol for ovalbumin after the reaction with 1 and a 
method to prove that 1 is attached to ovalbumin via the photocleavable side chain and not 
through the electrophilic site of the epoxide moiety. 
Conclusions 
The synthesis and purification of probe 1 required a strategy that allowed all 
coupling steps to be perfomed on a solid support. The target compound was obtained in 6% 
overall yield. The photocleavage characteristics of the nitrovaleryl linker were established. 
The labeling of ovalbumin with 1, in order to study the inhibition characteristics of the 
construct, needs optimization. The purity and homogeneity of ovalbumin labeled with 
probe 1 could not be confirmed, due to possible alkylation of ovalbumin via a cysteine thiol 
moiety. This would indicate that the labeling reaction of lysine with hydroxysuccimidyl 
ester is unsuitable to be performed in the presence of an epoxide moiety, and possibly an 
bioorthogonal labeling approach using the Staudinger ligation or Huisgen cyclization could 
produce efficient labeling of ovalbumin. 
Experimental part 
General methods and materials: Solvents used in the solid phase peptide synthesis, DiPEA and 
TFA were all peptide synthesis grade (Biosolve) and used as received. The protected amino acids, 
Rink amide MBHA resin (0.78 mmol g–1) and HCTU were obtained from NovaBiochem. Ethyl 
(2S,3S)oxirane-2,3-dicarboxylate was prepared as described in Chapter 4. Fmoc-Lys(Mtt)-OH was 
from Senn Chemicals, SPPS was carried out using a 180° Variable Rate Flask Shaker (St. John 
Associates, Inc.). LC/MS analysis was performed on a Jasco HPLC system (detection 
simultaneously at 214 and 254 nm) coupled to a Perkin Elmer Sciex API 165 mass spectrometer 
equipped with a custom-made Electrospray Interface (ESI). An analytical Alltima C18 column 
(Alltech, 4.6 × 250 mm, 5µm particle size) was used. Buffers: A: H2O; B: CH3CN; C: 0.5% aq. 
TFA. For RP HPLC-purifications a Biocad “Vision” automated HPLC system (PerSeptive 
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Biosystems, Inc.) was used. The applied buffers were A, B and C. 1H-NMR spectra were recorded 
with a Bruker DMX 600 instrument at 600 MHz with chemical shifts (δ) relative to 
tetramethylsilane. When appropriate, reactions were performed under the exclusion of light. 
Synthesis of 4-(4-(1-(succinimidylsuberoylamino)ethyl)-2-methoxy-5-nitrophenoxy)butanoic 
acid (9): A solution of known 4-(4-(1-(amino)ethyl)-2-methoxy-5-nitrophenoxy)butanoic acid6 (298 
mg, 1 mmol) and Et3N (0.14 ml, 1 mmol) in DMF (5 ml) was added dropwise to a solution of 
disuccinimidyl suberate (Alldrich, 386 mg, 1.3 mmol) in DMF (5 ml) and the mixture was stirred 
for 1.5 h until TLC-analysis (ethyl acetate) indicated a completed reaction. The mixture was 
concentrated in vacuo and the residue was taken up in ethyl acetate. The white precipitate was 
filtered off and the remainder solution was purified by silica gel chromatography (0-1% acetic acid 
in ethyl acetate) to yield 250 mg (0.45 mmol, 45%) of a faint yellow solid. 1H NMR (CDCl3): δ, 
7.56 (s, 1H), 7.19 (s, 1H), 6.52 (d, J=7.3 Hz, 1H), 5.6-5.4 (m, 1H), 4.2-4.0 (m, 2H), 3.92 (s, 3H), 
2.84 (s, 4H), 2.59 (t, 4H, J=7.3 Hz), 2.3-2.0 (m, 4H), 1.8-1.2 (m, 11H). ESI-MS C25H33N3O11 + H+ 
requires 552.2, found 551.9.  
Synthesis of 1: Fmoc-protected biocytinylated Rink amide resin (132 mg, 50 µmol) was elongated 
by standard Fmoc-based SPPS to give resin-bound Lys(Bio)Lys(Mtt)AhxTyr(tBu)Leu-Epoxirane. 
In brief, where appropriate removal of the Fmoc protecting group was accomplished by treatment of 
the resin-bound peptide with 20% (v/v) piperidine in NMP for 20 min. Peptide coupling steps were 
performed by treatment of the resin with a premixed (5 min) solution of the of the appropriate acid 
(5 eq.), HCTU (5 eq.) and DiPEA (6 eq.) in NMP (0.5 ml) for 1 hour unless stated otherwise. 
Coupling efficiencies were monitored with the Kaiser test and couplings were repeated if necessary. 
After coupling and deprotecting steps the resin was washed with NMP (5×). After the last coupling 
step, the resin was washed with CH2Cl2 (3×). Of 25 µmol of resin-bound 
Lys(Bio)Lys(Mtt)AhxTyr(tBu)LeuEpoxirane, the lysine side chain Mtt protecting group was 
removed by treatment with 1% TFA in CH2Cl2 (4×10 min). The resin was washed (CH2Cl2 5×, then 
NMP 2×) and neutralised with 10% DiPEA in NMP. To cooled (-20°C) resin was added a premixed 
(5 min) and cooled (-20°C) solution of active ester 8 (55 mg, 0.10 mmol), HATU (38 mg, 0.10 
mmol) and DiPEA (34 µl, 0.20 mmol) in NMP and the resin was agitated for 1 h, and allowed to 
warm to ambient temperature. The resin was washed extensively (alternating CH2Cl2-MeOH 3×, 
alternating CH2Cl2-Et2O 3×), transferred into a clean vial and treated with TFA/H2O/TIS (1 ml, 
95/2.5/2.5 v/v/v) for 1 h. The mixture was filtered and the resin washed with TFA (2× 1 ml). The 
filtrate was diluted (toluene, 10 ml) and concentrated in vacuo. The crude product was coevaporated 
(toluene, 3×) and purified to homogeneity by RP-HPLC, applying a linear gradient (20-55% B in 3 
column volumes) to yield 2.38 mg (1.5 µmol, 6.1%) of product. 1H NMR (DMSO, 300 K, DMX 
600): δ, 9.12 (s, 1H), 8.50 (d, 1H, J = 7.6 Hz), 8.44 (d, 1H, J 7.6 Hz), 8.07 (d, 1H, J = 8.2 Hz), 7.89 
Chapter 5 
 82
(d, 2H, J = 7.7 Hz), 7.83-7.77 (m, 2H), 7.77-7.65 (m, 6H), 7.46 (s, 2H), 7.14 (s, 1H), 6.99-6.91 (m, 
5H), 6.60 (d, 4H, J = 8.3 Hz), 6.41 (s, 1H), 6.34 (s, 1H), 5.38-5.31 (m, 1H), 4.37-4.26 (m, 5H), 
4.21-4.08 (m, 8H), 4.04-3.94 (m, 3H), 3.86 (s, 3H), 3.69 (d, 1H, J = 1.7 Hz), 3.57 (d, 1H, J = 1.7 
Hz), 3.11-3.04 (m, 3H), 2.83-2.74 (m, 6H), 2.73-2.50 (m, 8H), 2.23-1.88 (m, 12H), 1.67-1.09 (m, 
28H), 0.87-0.74 (m, 7H). ESI-MS: C74H109N13O22S + H+ requires 1564.8, found 1565.0; 
Conjugation of 1 to ovalbumin: Ovalbumin (22 nmol) was incubated with 1 (66 nmol, 5 µl of a 13 
mM stock in DMSO) in phosphate buffer (0.5 ml, 50 mM, pH 7.8) for 2 h at 4°C. To purify the 
labeled ovalbumin, the reaction mixture was filtered over a 10 kD cutoff filter and the resulting 
solution was lyophilized. A sample of the ovalbumin conjugate was boiled for 3 min in 4× Laemmli 
sample buffer (5% SDS, 46% glycerol, 0.156 mM Tris-HCl pH 6.8, 0.25% bromophenol blue, 1.4 
M β-mercaptoethanol in H2O) and resolved by 12.5% SDS-PAGE. Proteins were visualized by 
silver staining (Amersham). Western blotting and incubation with streptavidin-horseradish 
peroxidase (strept-HRP) conjugates allowed the visualization of biotinylated ovalbumin by 
chemiluminescence. 
Cathepsin activity profiling: 2 pmol Cat B (R&D Systems) was pre-incubated at 10 µg/ml in 25 
mM 2-(N-morpholino)ethanesulfonic acid (MES), 5 mM dithiothreitiol, pH 5.0 for 15 min at room 
temperature. Ovalbumin-1 conjungate (2 pmol) was incubated with the activated Cat B for 1 h at 
ambient temperature. The mixture was neutralized to pH 7 by addition of aq. NaOH (0.4 µl of a 1M 
solution) and resolved by 10% SDS-PAGE followed by Western blotting. Biotinylated proteins 
were visualized by chemiluminescence after incubation with strept-HRP. 
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Around a decade ago, it was found that specific oligopeptides can traverse lipid 
bilayers that make up the cell membrane of mammalian cells, and that they can do so when 
covalently bound to proteins or other relevant biomolecules. This property, which was first 
identified for peptides derived from the HIV-1 Tat2 and Drosophila Antennapedia3 (Ant) 
proteins, has attracted much attention. As a result, a wide variety of natural and synthetic 
peptides displaying transferring properties have been identified and used to deliver cargo 
into cells.4-6 Common to most of these sequences is the presence of numerous basic amino 
acid residues, as is evident in the Tat (GRKKRRQRRRPPQ) and Ant 
(RQIKIWFQNRRMKWKK) peptides. It is thought that these cationic residues are 
responsible for the translocation activity. 
To investigate the role of arginine residues further, oligoarginine peptides built from 
seven to eleven arginine moieties were used in uptake experiments. The group of Futaki 
showed that oligoarginine translocated both fluoresceine and carbonic anhydrase into RAW 
cells.7 The optimal number of arginine residues for translocation was found to lie between 
six and eight. Wender et al. synthesised both all-D and all-L oligoarginine peptides, and 
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demonstrated that both are capable of translocation of fluoresceine.8 They found that nine 
arginine residues were optimal to induce translocation, and that the all-D peptide is a better 
translocator than the corresponding all-L peptide. In another study,9 the uptake of 
fluoresceine conjugates with oligomers of arginine, lysine or histidine was compared, and it 
was found that only the oligoarginine conjugates effected fluorescence within cells. 
Octamers and nonamers of arginine exhibited comparable uptake efficiency, and again the 
all-D peptides residues performed better than the all-L peptides. 
The mechanism of translocation mediated by cell penetrating peptides still has to be 
revealed. From the observation that the all-D peptides are at least as efficient in 
translocation as the corresponding all-L peptides, it can be concluded that there is no 
specific receptor involved. There is, however, no consensus whether the translocation is 
caused by spontaneous permeabilisation of the cell membrane or by active uptake of the 
cargo via the endosomal pathway. Evidence supporting the latter option is accumulating 
slowly,10 but the possibility of multiple pathways can not be excluded yet. The endosomal 
pathway is a feature of the cell that is used to regulate uptake of nutritients and 
communication signals from the environment of the cell. There are different uptake 
pathways for molecules to enter the cell.11 Generally, the first step involves a membrane 
rearrangement resulting in the formation of a small, membrane enclosed vesicle in the 
cytosol. These vesicles can travel to the endoplasmatic reticulum or golgi apparatus, and 
deliver their cargo there, or enter the lysosomal pathway, resulting in the degradation of the 







































Figure 1. Target structures. 
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It was envisaged that involvement of the endosomal pathway could be demonstrated 
by the activity of lysosomal cysteine proteases, which may be visualised via a suitable 
activity based probe. Fusion of an activity based cysteine protease probe to the 
nonaarginine cell penetrating peptide would yield a probe that enters the cell in the fashion 
dictated by the nonaarginine sequence. Any cysteine protease that is encountered in the 
uptake pathway can be visualised, thus generating insight in the actual path that the probe, 
and thus the nonaarginine peptide, follows. For this purpose, two conjugates were 
synthesized of nonaarginine with DCG-04,13 a broad class cysteine protease activity based 
probe. The cell penetrating peptide is linked to DCG-04 either by a short hydrophobic or by 
a longer hydrophilic linker (compounds 1 and 2, figure 1). 
Synthesis 
The synthesis of probe 1 (Scheme 1) starts with the conjugation of nine Pbf-
protected arginine residues to the acid labile rink resin via standard Fmoc-based SPPS. 
Elongation of the growing peptide chain with an aminohexanoic acid spacer yields 
protected and immobilised 4. The biotin moiety was introduced by direct coupling of a side 
chain biotinylated lysine building block and the synthesis was continued by Fmoc-based 
SPPS furnishing peptide 8 on the solid support. Cleavage of the peptide from the solid 
phase with concomitant removal of the arginine en tyrosine side chain protecting groups 
gave endocytosis probe 1 in 11% overall yield after RP-HPLC purification. 
The synthesis of probe 2 was performed in a slightly different way. Rink resin was 
elongated with nine Pmc-protected arginine residues and spacer 9.14 The azide group in 
compound 3 was transformed to an amine by a Staudinger reduction. Elongation with 
Fmoc-Lys(Mtt)-OH and removal of the hyper acid-labile Mtt protecting group was 
followed by biotinylation of the lysine side chain to give immobilised 5. From that point, 
the synthesis was continued by Fmoc-based SPPS furnishing peptide 7 on the solid support. 



















7 R = Pmc, X = (CH2(OCH2CH2)3


































































5 R = Pmc, X = (CH2(OCH2CH2)3































Scheme 1. Synthesis of polyargininated cysteine protease probes 1 and 2. Reagents and 
conditions: General reagents for SPPS: Fmoc cleavage: 20% (v/v) piperidine in NMP; amino acid 
condensation: Fmoc protected amino acid, HCTU, DiPEA, NMP. a) Repeated cycles of SPPS: 
Building blocks employed: Fmoc-Arg(Pmc)-OH (9×), 9; b) Repeated cycles of SPPS: Building 
blocks employed: Fmoc-Arg(Pbf)-OH (9×), Fmoc-Ahx-OH; c) Me3P, 20% water in dioxane, then 
Fmoc-Lys(Mtt)-OH, HCTU, DiPEA, NMP; d) 1% TFA in CH2Cl2, then biotin, HCTU, DiPEA, NMP; e) 
20% piperidine in NMP, then Fmoc-Lys(Biotin)-OH; f) Repeated cycles of SPPS: Building blocks 
employed: Fmoc-Ahx-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Leu-OH, epoxirane 10; g) TFA/TIS/H2O 
(95/2.5/2.5 v/v/v), 3 h. Overall yield of 1 and 2: 11% and 13%, respectively. 
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Biological activity of the probes 
Next, the labeling efficiency of the newly synthesised probes was investigated. Cell 
lysates and endocytic extracts15 from different origin were incubated with 1, 2 or a broad 
class cysteine protease probe developed in Chapter 5 (11; Figure 2). The labeling with 1 
can be abolished by pre-treatment of the lysate with E-64,16 a broad-class cysteine protease 
inhibitor (Figure 3, lane 1), indicating that 1 is a label for active cysteine proteases. For the 
other lanes, it is of interest to note that cathepsins labeled with either 1 or 2 are modified 
with a probe that is 1.5 kD heavier than 11, and thus all cathepsin band are shifted 1.5 kD 
upwards. In U937 extracts (lane 2 and 3), probe 1 and 2 label only Cat S and Cat B, 
whereas 11 also hits Cat X (lane 4). In DC cell lysates, the new probes clearly target Cat B, 
which may appear as a double band (lane 5 and 6). Cathepsin probe 11 (lane 7) also hits Cat 
X and Cat S. Monocyte extract labeling with probe 1 and 2 (lane 8 and 9) shows Cat B, Cat 
H and Cat S. Again, 11 also labels Cat X. Overall, this experiment demonstrates that Cat B, 
Cat H and Cat S are targeted by 1 and 2 with an efficiency comparable to broad class 
cysteine protease inhibitor 11. 
Encouraged by these results, the labeling efficiency in living cells was addressed. In 
a pulse experiment, immature dendritic cells (DC) were incubated with control 11 or probe 
1. Immature DC are known for their high endocytic activity, whereas in mature DC 
endocytosis is greatly reduced.17 The cells were washed and lysed in the presence of JPM-
56518 to block remaining cysteine protease activity. The labeling of cysteine proteases was 
visualised via strept-HRP blotting (Figure 4). As a control, immature and mature dendritic 
cell lysates were labeled with 11 (lane 1 and 2), and it shows that maturity of the dendritic 
cells does not affect cathepsin labeling. In lane 3, 4 and 5, it is seen that labeling of Cat X, 




















































1 + + - - + - - + - - 
2 - - + - - + - - + - 
11 - - - + - - + - - + 





 1 2 3 4 5 6 7 8 9 10 
 
Figure 3. Labeling behaviour of 1 and 2 in cell lysates and endocytic extracts. Lysates and extracts 
were incubated with 1, 2 and 11 at 10 µM and ambient temperature for 30 minutes. In lane 1, the 
extract was pretreated with 40 µM E-64 for 1 hour. Samples were separated by SDS-PAGE and 
transferred to polyvinyliden difluoride membrane. Incubation with strept-HRP conjugate allowed the 
visualisation of active cathepsins. 
 
 Lysate DC Pulse  
1 - - - - - + + + +  
11 + + + + + - - - -  
LPS - + - - + - - + +  




 1 2 3 4 5 6 7 8 9  
 
Figure 4. Labeling of dendritic cells with probe 1 or 11. Cells were incubated for 1 hour with 10 µM 
of either 11 or 1. Cells were lysed in the precence of 100 µM JPM-565 and the labeling was 
addressed by developing a blot. 
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maturity. However, in comparable experiments (data not shown), labeling generally 
decreased upon maturation. This indicates that labeling with 11 is at least partly 
independent of endocytosis. In lane 6-9, cathepsin labeling is greatly reduced at 4°C 
relative to 37°C, but not blocked. This indicates contributions both of energy dependent and 
energy independent pathways. In mature cells (lane 9), the uptake is lower than in immature 
dendritic cells (lane 7), which indicates that endocytosis is a large component of the uptake 
in immature cells at 37°C. Interestingly, in mature cells the difference in uptake between 
4°C and 37°C (lane 8 and 9) is not so pronounced, which suggests that in mature cells no 
energy dependent pathway is employed for the uptake of the probe. This suggests that the 
energy-dependent component of uptake is abolished both at 4°C and by maturation, and 
endocytosis could be this component in both cases. 
Conclusion 
In this chapter, it is shown that a broad class cysteine protease probe that is hardly 
cell permeable can be made cell penetrating via the attachment of a nonaargine cell 
penetrating vector. The labeling of cysteine proteases with the new probes in living cells 
seems to be largely energy-dependent, because it is greatly reduced at 4°C. 
These probes may play a role in the elucidation of the pathway that is employed to 
take up nonaarginine vectors. Further experiments addressing the role of individual steps of 
the uptake pathway could help to gain insight in details of the uptake. Furthermore, it will 
be interesting to investigate the uptake efficiency and the targeting of cysteine proteases in 
other cell types or tissues. 
Experimental section 
General methods and materials: Solvents used in the solid phase peptide synthesis, DiPEA and 
TFA were all of peptide synthesis grade (Biosolve) and used as received. The protected amino 
acids, Rink amide MBHA resin (0.78 mmol/g) and HCTU were obtained from NovaBiochem. Ethyl 
(2S,3S)oxirane-2,3-dicarboxylate was prepared as described in Chapter 4. Fmoc-Lys(Mtt)-OH was 
from Senn Chemicals. SPPS was carried out using a 180° Variable Rate Flask Shaker (St. John 
Associates, Inc.) or on a 443A Peptide Synthesiser (Applied Biosystems). LC/MS analysis was 
performed on a Jasco HPLC system (detection simultaneously at 214 and 254 nm) coupled to a 
Perkin Elmer Sciex API 165 mass spectrometer equipped with a custom-made Electrospray 
Interface (ESI). High resolution mass spectra were recorded on a Finnigan LTQ-FT (Thermo 
electron). An analytical Alltima C18 column (Alltech, 4.6 × 250 mm, 5 µm particle size) was used. 
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Buffers: A: H2O; B: CH3CN; C: 0.5% aq TFA. For RP HPLC-purifications a Biocad “Vision” 
automated HPLC system (PerSeptive Biosystems, Inc.) was used. The applied buffers were A, B 
and C. 1H-NMR spectra were recorded with a Bruker DMX 600 instrument at 600 MHz with 
chemical shifts (δ) relative to tetramethylsilane. U937 cells were cultured on complete medium 
(RPMI 1640 medium supplemented with 2 mM L-glutamine, 10% fetal calf serum, and antibiotics).  
Solid phase peptide synthesis: Where appropriate removal of the Fmoc protecting group was 
accomplished by treatment of the resin-bound peptide with 20% (v/v) piperidine in NMP for 20 
min. Peptide coupling steps were performed by treatment of the resin with a premixed (5 min) 
solution of the appropriate acid (5 eq.), HCTU (5 eq.) and DiPEA (6 eq.) in NMP for 1 h. Coupling 
efficiencies were monitored with the Kaiser test and couplings were repeated if necessary. After 
coupling and deprotecting steps the resin was washed with NMP (5×).  
Synthesis of 1: Fmoc Rink amide resin (78 mg, 50 µmol) was elongated using automated standard 
Fmoc-based SPPS to give resin-bound (Arg(Pbf))9. The synthesis was continued by manual Fmoc-
based SPPS to give protected and resin-bound 8. The resin was washed extensively (alternating 
CH2Cl2-MeOH 3×, alternating CH2Cl2-Et2O 3×. An aliquot of resin (100 mg, 16 µmol) was 
transferred into a clean vial, washed with CH2Cl2 and treated with TFA/H2O/TIS (0.7 ml, 95/2.5/2.5 
v/v/v) for 2 h. The mixture was filtered into cold Et2O and the white precipitate was collected by 
centrifugation and decantation. The precipitate was washed (Et2O), followed by RP-HPLC 
purification of the crude product (linear gradient in B: 20-30% B in 3 column volumes) to yield 4.3 
mg (1.8 µmol, 11%) of product. 1H NMR (D2O, 295 K, DMX 600): δ, 7.08 (d, 2H, J = 7.9 Hz), 6.80 
(d, 2H, J = 8.2 Hz), 4.58-4.55 (m, 1H), 4.45-4.41 (m, 1H), 4.38-4.35 (m, 1H), 4.34-4.18 (m, 12H), 
4.13-4.09 (m, 1H), 3.68 (br s, 1H), 3.48-3.45 (m, 1H), 3.30-3.25 (m, 1H), 3.24-3.09 (m, 24H), 3.03-
2.86 (m, 4H), 2.79 (s, 1H), 2.69 (s, 1H), 2.28-2.18 (m, 6H), 1.80-1.20 (m, 61H), 0.89-0.80 (m, 6H). 
ESI-MS: C105H189N45O24S + 4 H+ requires 625.5, found 625.4; C105H189N45O24S + 3 H+ requires 
833.7, found 833.6. 
Synthesis of 2: Fmoc Rink amide resin (78 mg, 50 µmol) was elongated using automated standard 
Fmoc-based SPPS to give resin-bound 3. The azide moiety was reduced to an amine on solid phase 
by treatment of the resin, after washing (dioxane 5×), with Me3P (0.3 ml 1M in toluene, 0.3 mmol, 6 
eq.) in dioxane/H2O (4/1 v/v, 1 ml) for 40 min, followed by extensive washing of the resin (dioxane 
3×, alternating CH2Cl2-MeOH 3×, and NMP 3×). The peptide chain was elongated manually with 
Fmoc-Lys(Mtt)-OH and the lysine side chain Mtt protecting groups was removed by treatment with 
1% TFA in CH2Cl2 (4×10 min) The resin was washed (CH2Cl2 5×, then NMP 2×) and neutralized 
with 10% DiPEA in NMP. The lysine side chain amine was acylated with biotin to give resin-bound 
5. The synthesis was continued by manual Fmoc-based SPPS to give protected and resin-bound 7. 
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The resin was washed extensively (alternating CH2Cl2-MeOH 3×, alternating CH2Cl2-Et2O 3×. An 
aliquot of resin (55 mg, 10 µmol) was transferred into a clean vial, washed with CH2Cl2 and treated 
with TFA/H2O/TIS (0.7 ml, 95/2.5/2.5 v/v/v) for 3 h. The mixture was filtered into cold Et2O and 
the white precipitate was collected by centrifugation and decantation. The precipitate was washed 
(Et2O), followed by RP-HPLC purification of the crude product (linear gradient in B: 20-30% B in 
3 column volumes) to yield 3.3 mg (1.3 µmol, 13%) of product. 1H NMR (D2O, 295 K, DMX 600) 
δ, 7.09 (d, 2H, J = 8.3 Hz), 6.80 (d, 2H, J = 8.2 Hz), 4.58-4.55 (m, 1H), 4.47-4.43 (m, 1H), 4.38-
4.23 (m, 13H), 4.20-4.16 (m, 1H), 4.11 (s, 2H), 3.76-3.61 (m 20H), 3.59-3.55 (m, 2H), 3.54-3.50 
(m, 1H), 3.40-3.36 (m, 1H), 3.35-3.31 (m, 2H), 3.28-3.24 (m, 1H), 3.22-3.12 (m, 24H), 2.99-2.90 
(m, 5H), 2.69 (s, 2H), 2.24-2.20 (m, 4H), 1.82-1.20 (m, 60H), 0.88-0.80 (m, 6H). ESI-MS: 
C103H185N45O21S + 4 H+ requires 606.5, found 606.5; C103H185N45O21S + 3 H+ requires 808.3, found 
808.3. 
DC: Isolation and cultures: PBMC (peripheral blood mononuclear cells) were isolated by 
Ficoll/Paque (Life Technologies, Inc., Grand Island, NY) density gradient centrifugation of 
heparinized blood obtained from buffy coat of healthy volunteers from the blood bank of the 
University of Tübingen. Isolated PBMC were plated (1 × 108 cells/8 ml per tissue culture flask) into 
tissue culture flasks (cellstar 75 cm2, Greiner Bio-One GmbH, Frickenhausen, Germany) in 
complete medium. After 1.5 h of incubation at 37°C, nonadherent cells were removed, and the 
adherent cells (12–19% of the incubated cells) were cultured in complete medium supplemented 
with GM-CSF and IL-4 for 6 days.19, 20 For maturation, medium was supplemented with LPS 
(Sigma) at day 6 for additional 24 h. 
Isolation of monocytes: Human PBMC were freshly isolated from buffy coats of donor blood by 
density gradient centrifugation (Ficoll), followed by several washing steps with PBS and a Percoll 
gradient (PercollTM, Amersham Biosciences, Uppsala, Sweden) consisting of 12 ml 2× PBS and 14 
ml Percoll. After centrifugation four distinct layers become discernable, where (from top to bottom) 
the first contains debris and few thrombocytes, the second enriched monocytes with little 
lymphocytes and the remaining thrombocytes, the next layer is enriched for lymphocytes with little 
thrombocytes while the bottom phase contains remaining granulocytes and red blood cells. The 
second phase (containing the bulk of monocytes) was carefully collected. The majority of the 
remaining contaminating cells were T cells (15-20%) with small amounts of B cells present (<10%). 
Cells were kept on ice for all successive procedures to prevent non-specific stimulation. Generation 
of postnuclear supernatants immediately followed monocyte enrichment. 
Active site labeling of cysteine proteases and detection by streptavidin-blotting: Endocytic 
extracts of at least 1×108 U937 cells or at least 5×107 monocytes were prepared following the 
method described.15 DC lysates were prepared as follows: 5×105 immature DC were washed with 
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PBS, centrifuged and resolved with 100 µl 2× lysis buffer (100 mM citrate/phosphate, 2 mM EDTA, 
1% NP40, pH 5) and kept to lysis for 30 min at 4°C. After pelleting membrane fragments by 
centrifugation for 10 min at 13.000 rpm in an eppendorf-centrifuge, the supernatant contained crude 
cell lysate. 3 µg total endocytic protein of U937, 1.5 µg endocytic protein of primary monocytes or 
3 µg DC cell lysate protein was incubated with 10 µM of 1, 2 or 11 at ambient temperature for 30 
min. Reactions were terminated by addition of SDS reducing sample buffer and immediate boiling. 
Samples were resolved by 12.5% SDS-PAGE gel, and then blotted on a PVDF-membrane and 
visualised using strept-HRP and the ECL-detection kit. In lane 1, E-64 was competed against 1. The 
same amount of total endocytic protein was incubated with 40 µM of E-64 for one hour at ambient 
temperature, and 1 was added to a concentration of 10 µM. After 30 min, the reaction was 
terminated and samples were treated as described above. 
Uptake and labeling in living cells via a pulse experiment: At least 1×106 DC per time point were 
pulsed in complete culture medium (300 µl per time point) for 1 hour with 10 µM 1 or 11 at 37°C. 
Additionally, at least 1×106 DC were incubated for the same time with 10 µM of either 1 or 11 at 
4°C. After the pulse cells were washed to remove excess 1 or 11 at 4°C for four times by 
centrifugation, removing of supernatant and resolving the pellet in PBS. Cells were lysed with 50 µl 
of 2× lysis buffer (100 mM citrate/phosphate, 2 mM EDTA, 1% NP40, pH 7), supplemented with 
100 µM free JPM-565. SDS reducing sample buffer was added to 50 µg total protein of each time 
point and immediately boiled. 
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Summary and future prospects 
 
 
Organic synthesis has provided tools to study the proteasome and cysteine proteases 
of the cathepsin family. In this thesis, new tools are presented, extending the possibilities to 
study these proteolytic activities. In Chapter 1 of this thesis, an overview is presented of 
chemical labeling of biomolecules in living cells. Incorporation of unnatural reactive 
handles into native proteins, followed by employing these reactivities for the installation of 
a label, allowed selective tagging of a single protein in a cellular system. Another strategy 
of labeling a single protein was found in the creation of fusion proteins between the protein 
of interest and either a special peptide sequence or an active protein. The fusion proteins are 
labeled via the unnatural part with a fluorescent dye reacting specifically with the special 
peptide sequence. The third strategy explored, uses cell permeable activity based probes to 
introduce a latent bioorthogonal reactivity on active proteins, and after cell lysis, the 
reporter group of choice can be attached to the latent reactivity. 
In Chapter 2, an approach is described to target active proteasomes in living cells 
and detect the proteasomes after cell lysis via two-step labeling. After modifying active 
proteasome with an irreversible inhibitor that was equipped with an azide moiety, the 
Staudinger-Bertozzi ligation was employed to biotinylate the proteasome selectively. This 
is the first example in which all proteolytic activities of the proteasome in a cellular system 
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are visualized. In this way, labeling artifacts as associated with cell lysis and measuring 
enzymatic activities in cell lysates are precluded. The scope of this method could be 
extended by the use of different irreversible proteasome activity probes and different 
ligation methodology, such as the Huisgen cyclisation as applied by Cravatt and 
coworkers.1 
In Chapter 3, the two-step labeling approach presented in Chapter 2 was used to 
assess the specificity of two subunit-specific cell permeable inhibitors of the caspase-like 
activity of the proteasome. Based on studies towards reversible subunit specific proteasome 
inhibitors, an irreversible and cell permeable inhibitor was designed. Modification of the 
newly synthesized inhibitor with an azide moiety yielded a probe for the caspase-like 
activity of the proteasome. The selectivity of the newly synthesized probes was assessed 
both by peptidase assays and Western blots. At a lower concentration of the inhibitor, 
selectivity towards the immunoproteasome was observed. To investigate the role of the 
caspase like subunit of immunoproteasome in antigen processing, the epoxomicin2 (1, 
Figure 1) warhead and the peptide boronate known from bortezomib3 (2) combined with the 





















































Figure 1. Possible immunoproteasome inhibitors based on other warheads 
Furthermore, the technique of finding inhibitor targets by incorporation of a latent 
chemical group, like the azide moiety, in other irreversible inhibitors may contribute to 
elucidating the selectivity of the inhibitors and the identification of their minor targets. This 
could be of importance in recognizing side effects of drugs. In Figure 2, some azide-
modified cysteine protease inhibitors are depicted, that might be used for two-step labeling. 
Compound 5 is based on E-644, a natural product that is an inhibitor of cysteine proteases 
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of the cathepsin family, whereas inhibitor 6 is an 
azide modification of ZVAD-FMK5, an 
irreversible caspases inhibitor. 
Chapter 4 shows the synthesis of an 
isotope-coded activity based probe for cysteine 
proteases of the cathepsin class. A set of 
deuterium encoded spacer molecules suitable for 
incorporation by solid phase peptide synthesis 
were developed. Modification of a known broad class cysteine protease inhibitor with these 
isotope coded spacers did not impair the inhibitory profile. It was expected that by labeling 
two cysteine protease samples by an isotope coded inhibitor pair, the relative activity of 
cysteine proteases between two samples can be established by mass spectrometry. 
However, the detection of the expected isotope-labeled active site fragment of cathepsin B 
proved troublesome, and therefore an attempt was made to synthesise this fragment. The 
isotope coded linker developed in this chapter could also find their way into the proteasome 
inhibitor or biotinylation phosphine in presented in Chapter 2 to allow quantitation of 
proteasomal activity in living cells. Furthermore, the methodology could be extended by the 
use of other isotope labels, such as 13C, which is reported to have less effect of 
chromatographic separations.6 
Chapter 5 deals with the synthesis of a new cysteine protease probe. This probe is 
based on a known probe, extended both with an activated ester functionality that is reactive 
towards amines and an photolabile linker. The active ester was employed to conjugate the 
cysteine protease probe covalently to a model antigen. Presentation of this modified antigen 
to a professional antigen presenting cell could result in activity profiling of cysteine 
proteases involved in the proteolytic processing of the model antigen. The photolabile 
linker could be of importance to remove the remained of the model antigen from the labeled 
cysteine proteases, thereby simplifying the identification of the labeled cysteine proteases. 
Initial experiments involving the cleavage of the photolabile linker, the conjugation to 
ovalbumin as a model antigen and labeling of cathepsin B proved encouraging. However, 
the purity and homogeneity of the ovalbumin-probe conjugate could not be established yet. 
Some peptide sequences are known for their capacity to translocate through cell 




























rendering a construct that was actively transported into cells. Meanwhile, the cysteine 
protease probe sampled the pathway for active cysteine proteases. In a set of uptake 
experiments, it was shown that the uptake pathway has at least an energy-independent 
component. In future research, different cell penetrating peptides could be fused to a 
cysteine protease probe, in order to see if all peptide sequences dictate the same uptake 
mechanism. 
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Het bestuderen van functionele eiwitten in de context van de levende cel is een 
belangrijk veld van onderzoek. Dit proefschrift richt zich op het ontwerp en de synthese van 
probes waarmee de enzymactiviteiten van het proteasoom en van cysteineproteases van de 
cathepsine klasse kunnen worden gedetecteerd en gekwantificeerd. In Hoofdstuk 1 van dit 
proefschrift wordt een overzicht gegeven van de manieren waarop biomoleculen in levende 
cellen van een label kunnen worden voorzien. In natieve eiwitten kan een reactieve groep 
ingebouwd worden, die vervolgens wordt gebruikt om het eiwit selectief van een label te 
voorzien. Een andere strategie omvat de biosynthese van fusie-eiwitten die bestaan uit het 
te bestuderen eiwit en een speciaal peptide of actief enzym. Het toegevoegde deel van het 
fusie-eiwit maakt het aanbrengen van een label mogelijk. De derde strategie maakt gebruik 
van speciaal ontworpen synthetische probes, die celpermeabel zijn. Deze probes binden 
covalent aan het te onderzoeken eiwit en zijn bovendien voorzien van een bio-orthogonale 
groep die inert is in de cellulaire omgeving, maar na cellysis wordt gebruikt voor het 
aanbrengen van een label. 
In Hoofdstuk 2 worden de synthese en toepassing van een nieuw type probe 
beschreven. Een bekende cel permeabele en irreversibele remmer van het proteasoom werd 
uitgerust met een azide als bio-orthogonale groep. Na incubatie van cellen met deze probe 
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en cellysis, kon het proteasoom middels de Staudinger-Bertozzi ligatie selectief worden 
gebiotinyleerd. Met deze tweestapsprocedure konden voor het eerst alle proteolytische 
activiteiten van het proteasoom in de levende cel zichtbaar worden gemaakt en werden 
mogelijke artefacten, die kunnen optreden bij het lyseren van cellen en het meten van 
enzymactiviteiten in cellysaten, voorkomen. 
Het proteasoom vertoont verschillende soorten enzymatische activiteit, die 
gelokaliseerd zijn in afzonderlijke subunits. In Hoofdstuk 3 worden twee remmers 
gepresenteerd voor één van deze activiteiten van het proteasoom, namelijk degene die wat 
substraatherkenning betreft op caspases lijkt. Een van deze nieuwe remmers bevat een 
azidegroep, en de specificiteit van deze remmer voor de caspase-achtige activiteit van het 
proteasoom werd aangetoond middels de tweetrapsprocedure uit Hoofdstuk 2. Bij een 
lagere concentratie van de remmer werd bovendien selectiviteit voor het 
immunoproteasoom waargenomen. 
Hoofdstuk 4 beschrijft de vaste drager synthese van twee paar probes voor cysteine 
proteases uit de cathepsineklasse. Kenmerkend voor deze probes zijn de speciale linkers, 
namelijk één in een lichte vorm, en de ander in een zware vorm, waarin een aantal 
waterstofatomen is vervangen door deuterium. Het inbouwen van de nieuwe linker in een 
bekende cathepsineremmer had geen invloed op het remmingsprofiel. Met behulp van een 
lichte en een zware probe zou de relatieve cysteine proteaseactiviteit tussen twee samples 
middels massaspectrometrie kunnen worden vastgesteld. Voorwaarde voor succes van deze 
methode is de massaspectrometrische detectie van het door de remmer gealkyleerde active 
site fragment van het enzym. 
Hoofdstuk 5 behandelt de synthese van een nieuwe cysteine protease probe. Deze 
probe omvat een bekende remmer voor cysteine proteases die via een fotolabiele linker 
werd uitgebreid met een geactiveerde ester. De actieve ester werd gebruikt om een 
covalente binding tot stand te brengen tussen de probe en de aminogroepen van een 
modelantigeen. Door dit gemodificeerde antigen aan te bieden aan een professionele 
antigen presenterende cel zouden de cysteineproteases, die een rol spelen bij de verwerking 
van dit antigen voor presentatie, in kaart gebracht kunnen worden. De identificatie van deze 
proteases zou vereenvoudigd kunnen worden door het verwijderen van het modelantigeen 
door de invloed van ultraviolet licht op de fotolabiele linker. De eerste 
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labelingsexperimenten verliepen echter niet eenduidig, wat mogelijk een gevolg is van een 
inhomogeniteit van het gemodificeerde antigen. 
Sommige peptidesequenties zijn bekend om hun eigenschap andere moleculen door 
celmembranen heen te transporteren. Het mechanisme van dit transport is nog niet volledig 
opgehelderd. In Hoofdstuk 6 wordt een benadering gepresenteerd die het inzicht in het 
opnamemechanisme kan vergroten. Een cysteine protease probe werd geconjugeerd aan een 
celpenetrerende peptidesequentie, opdat dit construct actief cellen in wordt getransporteerd. 
Tijdens het transport bindt de probe aan de actieve cysteine proteases die het onderweg 
tegenkomt. In een reeks experimenten werd aangetoond dat het opnamepad minimaal een 
energieonafhankelijke component kent. In toekomstig onderzoek zouden verschillende 
celpenetrerende peptiden aan een cysteine protease probe kunnen worden geconjugeerd om 
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